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proteins.. In. most. instances,. we. would. not. even. know. what. the. contami-
nants.are.
The. Food. and. Drug. Administration. (FDA). and. European. Medicine.
Agency..(EMEA).thus.strongly.urge.manufacturers.to.create.environments.
that.would.keep.the.contaminants.out.rather.than.trying.to.clean.them,.and.




not. comply. with. the. new. requirements. shut. down,. and. a. new. awareness.














Before. moving. further. into. the. historical. perspective. of. disposable. com-
ponents,.it.is.necessary.that.we.review.the.regulatory.definition.of.the.term.
“single-use,”.which. is.only. in.context.with.devices..SEC..201.. [21.U.S.C..321].
Definitions. states:. (ll)(1). “The. term. ‘single-use. device’. means. a. device. that.
is. intended. for. one. use,. or. on. a. single. patient. during. a. single. procedure.”.
“Disposable”.is.defined.by.the.Oxford English Dictionary.as.“made.to.be.thrown.











processing. are. of. a. disposable. type,. these. are. still. not. in. the. mainstream.
of.manufacturing.for.many.reasons.including.the.lingering.questions.about.
the. quality. of. materials. used,. scalability,. running. costs,. level. of. automa-
tion.possible.with. these.components,.and. the. training.of. staff. required. to.
assimilate. these. components. in. an. established. bioprocessing. system.. The.

















This. book. is. the. first. attempt. to. consolidate. the. state. of. the. disposable.




The. author. has. had. firsthand. experience. in. establishing. the. first. max-












posable. systems,. every. piece. of. information. and. knowledge. in. making.
good.judgments.











refolding.proteins. to.storage.of. in-process.and.finished.product..Since. the.
container.must.be.compatible.with. the.product,. these.components.require.




need.not.be. sterilized.and.reused.made. the.development.of. several.novel.
devices.to.mix.the.contents.in.disposable.bags;.the.choices.range.from.impel-
lers. to. magnetically. levitating. spinners. and. air. flow. mixers.. This. chapter.













a. significant. role. in. designing. a. complete. disposable. bioprocessing. chain..
Since.these.components.have.been.around.for.the.longest.time.and.their.util-
ity.well.established,.it.is.easier..to.choose.correct.components.since.these.are.
also. subject. to. the. same.safety.evaluation.as. the.bioreactors..This. chapter.










choices. are. now. available.. This. chapter. advises. on. deciding. whether. it. is.
appropriate.to.consider.disposable.downstream.systems.because.of.the.high.
cost.and.diminishing.returns.on.the.efficiency.of.these.systems.
Chapter. 9.. Filling. and. Finishing. Systems.. The. manufacturing. systems.













Chapter. 11.. Regulatory. Compliance.. The. largest. cost-savings. in. the. use.
of. disposable. systems. comes. from. reduced. regulatory. barriers;. generally.
not.accounted.for.in.the.overall.design.of.bioprocessing.systems,.this.aspect.
requires.a.greater.understanding..This.chapter.describes.how.using.dispos-























and. others. who. made. significant. contribution. to. this. book. are. greatly.
appreciated.





















This.book.can.be.considered.a.sequel. to.my.book.Handbook of Biogeneric 












ing. the. stainless. steel. vessel;. by. adopting. a. 2D. flexible. bag. to. work. as. a.








Sarfaraz. K.. Niazi. has. been. teaching. pharmaceutical. sciences. and. con-
















to. numerous. breakthroughs. in. biological. science. and. inspired. a. genera-
tion.of.entrepreneurs..The.1980s.and.1990s.saw.a.booming.biotech.industry.
introducing.many.biologic.products.to.the.market..As.with.small-molecule.









therapeutic. proteins,. double-digit. growth. was. reported. for. insulin. and.
insulin.analogs.(+17%).and.recombinant.coagulation.factors.(+16%),.whereas.
modest.growth.(4%.to.7%).was.observed.for.therapeutic.proteins,.except.for.








The. engine. for. biological. manufacturing. comes. from. ever-improving.
expression.systems,.and.Table 1.1.gives.examples.and.their.status.as.of.today..


































































































industry.. Many. blockbuster. biologics—such. as. Enbrel. (etanercept. from.








































biological.manufacturing.are.of. little. importance.as. the.exposure. to. these.

























Procedures. (GMP). production.. Other. disposable. technologies,. such. as.








nizations. (CMOs). that.were.ready.to.fill. the.gap.. It.became.relatively.easy.


















Category. II. includes. line. items. that.were.necessitated.by. the.problems.













This. is. the. current. state. of. the. use. of. disposable. systems. as. of. 2010.
(BioProcess.International.Survey.summary):
. 1..The.use.of.disposable.bioprocessing. is.growing.at. the.rate.of.30%.
per.year.



















. 8..More. than. 80%. of. new. products. utilize. disposable. systems,. and.
















































































know. as. “advertorials”. describing. new. technology. and. its. benefits.. Some.














A. case. in. point. is. Amgen’s. retrofitted. recombinant. protein. manufactur-
ing.in.West.Greenwich,.Rhode.Island..Amgen.invested.about.US$500.M.to.
enable.manufacture.of.its.blockbuster.drug.Enbrel.(etanercept),.whose.patent.




use. Immunex’s. T1. Enhanced. Process. developed. by. the. Immunex. Process.













rently. the. largest. in.Europe..The.campus,.which.makes.Wyeth. the. largest.
pharmaceutical.employer. in. the.Republic.of. Ireland.with.1,370.employees,.
comprises.a.development.facility.as.well.as.a.drug.substance.and.drug.pro-
duction. facility,. representing. 1.2. million. ft². in. building. space.. The. site. is.
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2009..Products. that.are.manufactured.at. the.new.biotech. facility. include.
Enbrel. (etanercept),. Prevenar. (pneumococcal. conjugate. vaccine),. antihe-
mophilic. factor. VIII,. recombinant. human. bone. morphogenetic. protein.
(rhBMP-2),. Tygacil. (tigecycline. IV),. and. Relistor. (methylnaltrexone. bro-
mide).. Construction. required. more. than. 15,000. tons. of. structural. steel,.


























































up.and.validate.several.batch.sizes.and,. instead,. invest.money. in.doing.a.
good.job.at.Process.Analytical.Technology.(PAT).qualification.
Although. disposable. technologies. have. delivered. success. in. develop-
ment. laboratories. and. GMP. production. suites,. challenges. and. improve-
ment. opportunities. yet. remain.. For. example,. concerns. with. extractables.
and. leachables. have. not. been. fully. resolved. even. though. they. have. been.
addressed.in.detail..System.integrity.issues.could.lead.to.contaminations.or.
loss.of.product..Product.quality.consistency.and.lot-to-lot.variability.pres-

























however,. recently. changed. with. sparged. 2D. flex. reactors. (www.mayabio.
com),.and.now.the.choice.is.wide.open.for.every.type.of.cell.or.organism..
There. are. also. limitations. with. disposable. centrifuges. for. harvesting. the.
product.after.fermentation..Customers.generally.implement.new.technolo-
gies.after.they.are.truly.tested.and.well.proven.
Another. technical. issue. that. can. delay. the. acceptance. of. disposable.
solutions. is. scale.. Many. of. these. disposable. solutions. cannot. be. scaled.











internal. mixers,. and. other. components,. making. the. whole. system. more.
complex.and.less.plug.and.play.or.unplug.and.throw.away..One.loses.the.
level.of.containment,.and.one.has.a.lot.more.handling,.introducing.risks.
and. being. less. amenable. to. lean. approaches.. However,. for. many. appli-





Manufacturing. Practices. (cGMP). conditions.. Single-use. technologies.
are.powerful.strategic.tools.for.smaller.companies.who.need.to.advance.
their. early. stage. drugs. to. Phase. 2. or. even. Phase. 3. clinical. trials. before.















manufacturing. technologies. in. the. production. of. biopharmaceuticals. and.
vaccines..BPSA.facilitates.education,.sharing.of.best.practices,.development.



































































































































































































































































































































posable. solutions. for. entire. biomanufacturing. steps.. The. FlexAct.
system.consists.of.the.central.operating.module.that.offers.the.wid-
est.variety.of.configuration.options,.so.one.can.take.complete.control.
of. practically. any. steps. in. upstream. and. downstream. processing..
FlexAct. CDS. offers. configurable. disposable. solutions. for. buffer.
preparation. (BP),. cell. harvest. (CH),. virus. inactivation. (VI),. media.
preparation.(MP),.and.virus.removal.(VR)..Next.in.line.are.UF.DF.












. 3..Allegro™. Disposable. Systems—Recommended. capsule. filters.
and.membrane





. 8..Stax™. Disposable. Depth. Filter. w/. Seitz®. AKS. Activated. Carbon.
Media
















































































































































































































































include. all. steps. of. upstream. and. downstream. processing.. These. compo-
nents.include
. 1..Bioreactors








pletely. scaleable. across. our. platform. ranging. from. 200. mL. to.
500.L.
. 2.	Disposable	bioreactor	bags
Manufactured. from. multilayered. laminated. clear. plastic,. Cellbag.
disposable.bioreactors.are.suitable. for.specific.cell.culture.pro-
cess.needs.for.research,.development,.or.cGMP.manufacturing.






ReadyCircuit. assemblies. comprise. bags,. tubing,. and. connec-
tors.. Together. with. ReadyToProcess. filters. and. sensors,.
ReadyCircuit. assemblies. form. self-contained. bioprocessing.











with. ease. online.. Enter. the. parameters. to. generate. the. design.






















































Leachables. are. chemicals. that. migrate. from. disposable. processing. equip-
ment. into. various. components. of. the. drug. product. during. manufactur-



















deaths..While. the.source.of. the.PRCA.induction.is.not.clearly.settled,. it. is.
generally.attributed.to.a.change.in.the.drug.formulation.that.included.a.new.











Unlike. metals,. where. the. risk. lies. mainly. in. oxidation,. polymers. are.
affected. by. heat,. light,. oxygen,. and. autoclaving. and,. thus,. degrade. over.
time.if.not.stabilized,.and.this.can.adversely.affect.the.mechanical.prop-





molecular. structure,. the. polymerization. process,. the. presence. of. residual.
catalysts,. and. the. finishing. steps. used. in. production.. Processing. condi-
tions.during. extrusion. (e.g.,. temperature,. shear,. and. residence. time. in. the.
extruder).can.dramatically.affect.polymer.degradation..End-use.conditions.
that. expose.a.polymer. to.excessive.heat.or. light. (such.as.outdoor.applica-
tions.or. sterilization. techniques.used. in.medical. practices). can. foster.pre-












•. Long-term. thermal. stabilizers. that. provide. defense. against. heat.
encountered.in.end-use.applications.(e.g.,.hindered.phenols.and.hin-
dered.amines)
•. Light. stabilizers. that. provide. ultraviolet. (UV). protection. through.
mechanisms. such. as. radical. trapping,. UV. absorption,. or. excited-
state.quenching
One.application.in.which.an.additive.can.improve.or.alter.the.performance.
of. a. polymer. is. a. filler. or. modifier. that. affects. its. mechanical. properties..
Additives. known. as. plasticizers. can. affect. the. stress–strain. relationship. of.
a.polymer..Polyvinylchloride. (PVC). is.used.for.home.water.pipes.and. is.a.
very. rigid.material..With. the.addition.of.plasticizers,.however,. it.becomes.
very.flexible.and.can.be.used.to.make.intravenous.(IV).bags.and.inflatable.




Additives. are. not. always. single. entities.. Some. are. manufactured. from.
naturally.occurring.raw.materials.such.as.tallow.and.vegetable.oils.that.are.
themselves. composed. of. many. different. components. and. can. vary. from.
batch. to. batch.. Others. are. considered. “products. by. process,”. as. they. are.
formed.during.processing.by.adding.several.starting.materials.to.affect.the.




















containing. rubbers. (e.g.,. brominated. or. chlorinated. isobutylene. isoprene)..
If. not. neutralized,. anions. cause. premature. aging. and. a. decrease. in. the.
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performance.of.rubber.articles.over.time..Metal.oxides.can.be.very.efficient.
acid.scavengers.. Ions.of.copper. (Cu),. iron.(Fe),.cobalt. (Co),.nickel. (Ni),.and.
other.transition.metals.that.have.different.oxidation.states.with.comparable.
stability.are.called.rubber poisons.because.they.are.easily.oxidized.or.reduced.
by. one-electron. transfer.. They. are. very. active. catalysts. for. hydroperoxide.








































Commercially. supplied. plastic. films. are. proprietary. formulations. and.
arrangements;.for.example,.Advanced.Scientific.produces.its.bags.utilizing.
two. films.. The. fluid. contact. film. is. a. 5.0. mm. polyethylene.. The. outer. is. a.
5-layer.7.mil.co-extrusion.film.that.provides.a.barrier.and.durability..A.typi-
cal.test.report.is.given.in.Table 2.1.













































































































































Skin A x x x
B x x x
C x x x
Mucosal.Membrane A x x x
B x x x o o o




A x x x o
B x x x o o o




Blood.Path,.Indirect A x x x x x
B x x x x o x




A x x x o
B x x o o o x x
C x x o o o x x
Circulating.Blood A x x x x o^ x
B x x x x o x o x
C x x x x x x o x
Implant.Devices Tissue/Bone A x x x o
B x x o o o x x
C x x o o o x x
Blood A x x x x x x
B x x x x o x x x











line. for. evaluating. the. risk. associated. with. extractables. and. leachables,.
specifically. for. single-use. processing. equipment.. This. organization. is.





The. testing.for. leachables.should.not.necessarily.end.once. the.materials.




remove.most.of. these. leachables..Also,. the.final.medium.used. for.protein.
solutions.is.aqueous,.and.many.of.the.leachables.are.not.soluble.in.water:.this.
further.reduces.the.risk..Greater.risk.can.be.seen.in.the.final.packaging.com-


























Reputable. vendors. often. have. extractables. data. already. on. hand. to. share.
with.customers..In.many.cases,.they.will.provide.a.certificate.of.analysis.and.
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toxicological. information. associated. with. materials. used. to. fabricate. their.











ditions. that. are. more. severe. than. normally. found. in. a. biopharmaceutical.
process,.typically.using.a.variety.of.solvents.at.high.temperatures..The.goal.
of.an.extractable.study. is. to. identify.as.many.compounds.as.possible. that.





Not. all. leachables. may. be. found. during. the. extractables. evaluation.
because. drug. formulation. components. or. buffers. may. interact. with. a.
polymer.or.its.additives.to.form.a.new.“leachable”.contaminant.that.was.





















Extractables. and. leachables. generally. would. be. considered. “additive,”.
although.it.is.also.possible.for.leachables.to.interact.with.a.product.to.yield.
new.contaminants.
The. U.S.. FDA. regulatory. guidance. for. final. container–closure. systems,.
though.not.written.for.process-contact.materials,.gives.directions.about.the.
type. of. final. product. testing. that. may. be. provided. regarding. extractables.
and.leachables.from.single-use.process.components.and.systems..The.May.







































•. Compatibility of materials:. Most. biological. drugs. formulations. are.
aqueous. based,. and. therefore. compatible. with. the. materials. used.












because. they. may. reduce. associated. risk.. However,. it. cannot. be.
assumed. that. a. step. that. can. potentially. remove. some. leachables.





latory.and.safety. concern. for.potential. leachables.. Neutral.buffers.
lower.concern.about.potential.leachables.
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•. Time and temperature:. Longer. contact. times. allow. for. more. poten-
tial. leachables. to.be. removed. from.a.material.until. equilibrium. is.
reached..Higher.temperatures.lead.to.more.rapid.migration.of.leach-
ables.from.materials.into.a.process.stream.or.formulation.
•. Pretreatment steps:. Sterilization. by. steam. autoclave. and/or. gamma.
irradiation. may. cause. higher. levels. of. extractables. and. leachables.
depending. on. the. polymer. formulation. involved. in. a. single-use.
component..On.the.other.hand,.rinsing.may.lower.the.concern.for.
extractables.and.leachables.(e.g.,.when.filters.are.flushed.before.use).
Here. are. some. highlights. relating. to. risk. assessment. of. extractables. and.
leachables:
. 1..Regulatory. responsibility. for. overall. assessment. and. understand-




. 2..All. elastomeric. and. plastic-based. materials. contain. extractables.
specific. to. the. formulated. and. cured. materials. from. which. they.
are.constructed.
. 3..Contaminants. are. also. found. in. stainless. steel. systems. in. the. form.
of.residues.left.after.cleaning.or.traces.of.metals.such.as.iron,.nickel,.
and. chromium. salts. from. the. stainless. steel. itself,. so. the. problem.
of. contamination. from. the. container. is. not. restricted. to. disposable.
containers.
. 4..Most.polymers.without.certain.additives.would.not.work.as.mate-
rials. of. use. in. disposable. processing:. this. includes. stabilizing. the.
polymer,.extruding.it,.and.preventing.its.oxidation.and.UV.degra-
dation;.other.additives. include.antistatic. agents,. impact.modifiers,.





























upon.contact.with.a.product.stream:. leachables.are.a. result.of. the.
nature.of.the.product,.the.length.of.exposure,.and.the.environmental.
conditions.for.the.storage.of.the.product.
. 10..Detection. of. a. toxic. or. otherwise. undesirable. extractable. under.




in. question.. Techniques. such. as. Soxhlet. extraction,. solvent. reflux-









. 12..Toxicology. of. leachables. should. be. performed. using. approved. pro-
tocols.. A. Product. Quality. Research. Institute. (PQRI). document. on.
extractables.and.leachables.suggests.an.approach.to.address.toxicol-
ogy.using.LD50.with.a.1,000×.or.10,000×.safety.factor.based.on.the.
dosage. quantity.. In. addition,. several. structure–activity. relationship.
(SAR). databases. are. readily. available. to. professional. toxicologists..
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Examples. include. the. “Carcinogenic. Potency. Database”. (CPDB,.
http://potency.berkeley.edu/).and.the.U.S..Environmental.Protection.
Agency’s. “Distributed. Structure-Searchable. Toxicity. Network”.
(DSSTOX,. http://www.epa.gov/ncct/dsstox/). database.. Chances. are.
that.most.sponsors.will.not.be.able.to.conduct.these.studies.in-house,.
and.it.is.advised.to.outsource.these.evaluations.
. 13..The.classes.of.compounds. that.extractables. include,.more.particu-
larly,. n-nitrosamines,. polynuclear. aromatics. (sometime. termed.
polyaromatic hydrocarbons,.PAH),.and.2-mercaptobenzothiozole,.along.
with. biologically. active. compounds. such. as. bisphenol-A. (BPA)..
Individual. extractable. compounds. are. too. numerous. to. list,. but.
examples.include.aromatic.antioxidants.such.as.butylated.hydroxy-
toluene.(BHT),.oleamide,.bromide,.fluoride,.chloride,.oleic.acid,.eru-
camide,. eicosane,. and. stearic. acid.. Databases. on. extractables. are.
widely.available,.such.as.by.PQRI..Comprehensive.extractable.data.
for.components.can.reduce.the.time.and.resources.needed.to.qualify.
leachables. from. the. systems. where. they. are. used.. When. compar-
ing.supplied.extractables.data.for.components.constructed.of.similar.
materials,. end-users. should. carefully. review. the.methods.used. to.




























cess.uses.gamma. irradiation. for. sterilization,. then. the. component.






appropriate,. an. organic. solvent. with. the. appropriate. solubility.
parameters. will. help. identify. additional. extractables.. Extractions.
should. be. performed. at. relatively. extreme. time. and. temperature.
conditions.. However,. the. solvents. or. extraction. conditions. should.
not.be.so.extreme.as.to.degrade.materials.to.a.point.at.which.they.are.




. 20..Analytical. methods. should. include. HPLC. and. GC-MS. methods. to.






. 21..While. it. is.desirable. to. identify.each.extractable,. for. some.extract-
ables,. such. as. siloxanes. and. oligomers. of. base. polymers,. precise.
identification.is.not.feasible.because.of.the.large.number.of.closely.
related.isomers.and.oligomers..In.such.cases,.a.general.classification.
can.be.used..Quantitation.of. identified.extractables. is. informative,.
but.it.does.not.need.to.be.performed.at.a.high.level.of.precision..This.
is. different. from. recommendations. for. evaluating. extractables. for.
final. containers.or. closures,. for.which.analytical.and. toxicological.
limits.should.be.set.based.on.a.measured.level.of.extractables.
. 22..User-specific. components,. such. as. filters,. connecters,. tubing. and.
bags,.etc.,.may.be.built.by.using.subcomponents.from.different.ven-
dors..It.is.unlikely.that.the.composite.system.would.have.complete.






. 23..Biocompatibility. testing. is. a. very. complex. issue.. It. is. a. materi-
al’s. lack.of. interaction.with. living.tissue.or.a. living.system.by.not.




Biological. Evaluation. of. Medical. Devices,. which. has. replaced. the.
USP.Class.VI.test.















. m.. Identification. and. quantification. of. degradation. products. from.
polymeric.medical.devices
. n.. Identification. and. quantification. of. degradation. products.
from.ceramics
. o.. Identification. and. quantification. of. degradation. products. from.
metals.and.alloys








. 25..The.USP.88.protocols.are.used. to.classify.plastics. in.Classes. I–VI,.
based.on.end.use,. type,. and. time.of. exposure.of.human. tissue. to.
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plastics,.of.which.Class.VI.requires.the.most.stringent.testing.of.all.
the. six. classes.. These. tests. measure. and. determine. the. biological.
response.of.animals.to.the.plastic.by.either.direct.or.indirect.contact,.
or. by. injection. of. the. specific. extracts. prepared. from. the. material.
under.test..The.tests.are.described.as
. a.. Systemic. toxicity. test to. determine. the. irritant. effect. of. toxic.
leachables.present.in.extracts.of.test.materials






















device. with. the. body.. The. device. materials. should. not. either. directly. or.
through.the.release.of.their.material.constituents:.(i).produce.adverse.local.
or. systemic. effects;. (ii). be. carcinogenic;. or. (iii). produce. adverse. reproduc-
tive.and.developmental.effects..Therefore,.the.evaluation.of.any.new.device.
intended.for.human.use.requires.data.from.systematic.testing.to.ensure.that.
the. benefits. provided. by. the. final. product. will. exceed. any. potential. risks.
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produced.by.device.materials..When.selecting.the.appropriate.tests.for.the.
biological. evaluation. of. a. medical. device,. one. must. consider. the. chemical.





















tests. are. required. for. the. demonstration. of. substantial. equivalence. under.
section.510(k)..In.such.situations,.the.manufacturer.must.document.the.use.
of.a.particular.material. in.a. legally.marketed.predicate.device.or.a. legally.
marketed.device.with.comparable.patient.exposure.





















is.a.biocompatibility.flow.chart. for. the.selection.of. toxicity. tests. for.510(k)
s..It.may.be.applicable.to.some.Pharmaceutical.Manufacturers.Associations.
(PMAs).also.but.not.all.PMAs..In.addition,.the.FDA.is.in.the.process.of.pre-
paring. toxicology.profiles. for.specific.devices..These.profiles.will.assist. in.
determining. appropriate. toxicology. tests. for. these. devices.. To. harmonize.















does. not. require. irritation,. systemic. toxicity,. and. acute,. subchronic,. and.
chronic.toxicity.tests..Therefore,.the.FDA.has.included.these.types.of.tests.





Reviewers. should. avoid. a. proscriptive. interpretation. of. the. matrix.. If.
a.reviewer.is.uncertain.about.the.applicability.of.a.specific.type.of.test.for.

















































































































































































































































































































































































































































































































































































































































Does it contain any
toxic substances






















has acceptable tax data
applicable to the device.
Submission contains
acceptable tax data and/or
justification or risk assessment


























do. it. better.. Every. seed. destroys. its. container. or. else. there. would. be. no.
fruition..
Florida	Scott-Maxwell
Disposable. containers. form. the. heart. of. any. comprehensive. max-dispo.





































































•. Contour. Tank. Liners. are. a. cost-effective. alternative. to. dedicated.
tanks.and.totes..Contour.liners.reduce.cleaning.validation.and.ster-
ilization. of. traditional. containers.. Most. importantly,. because. they.
are.single.use,.the.potential.of.cross-contamination.between.differ-
ent.products.is.reduced.
•. Bio-Pak®. Totes. are. application-designed. mobile. totes. mounted. on.





genic. temperature. applications. under. liquid. nitrogen. conditions,.
and.are.used.predominately.for.clinical.and.research.applications..








top. or. bottom. drain,. and. available. as. a. liner,. fit. most. cylindrical.
tanks.and.is.available.as.a.manifold.system.



























































to. 3,500. L. in. size.. These. bags. are. produced. from. two-layer. films. that. are.
welded. together. at. their. ends.. The. result. is. a. flat. chamber. that. has. ports.
either.face.welded.or.end.welded..The.choice.of.ports.is.determined.by.the.
user.and.most.suppliers.have.standard.combinations.that.might.work.well.




































achieved. in.several.ways,. the.cheapest.one.being.wrapping. them. in.blan-
kets. that.are. temperature.controlled,.and.the.most.expensive.being.to.use.






































and,.while. they.survive. freeze–thaw.cycles,. it. is.often.difficult. to.
record.breaches. in. their. integrity,. thus.requiring.an.outer.protec-
tive.surface.











tems.. Some. of. the. keys. to. mixing. operations. include. mixing. to. dissolve.
components.of.a.buffer,.culture.media,.refolding.solution,.dispersion.of.cell.
culture.in.bioreactors,.and.heating.or.cooling.of.liquids.
All. mixing. operations. must. be. fully. validated. as. part. of. PAT. to. ensure.
that.optimal.mixing.has.been.achieved.all.the.time..While.the.stainless.steel.
mixing.vessels.have.long.been.used.and.the.principles.behind.mixing.and.




leads. to. the. dissolution. of. solutes,. and. the. other. that. provides. a. homog-
enous.environment.such.as.in.a.bioreactor.or.a.refolding.tank..How.fast.a.
mixture.of.powdered.components.in.a.buffer.mixture.dissolves.will.depend.








gives.a.measure.of. the.ratio.of. inertial. forces. to.viscous. forces.and.conse-




























































•. XDM.(Xcellerex),. 100.L. to.1,000.L,. the.XDM.Quad.Mixing.System.
comprises. an. integrated. magnetic. stirrer. with. a. compact.motor,. a.
bottom-mounted.disposable.stirrer;.the.coupling.between.the.motor.
and. the. disposable. stirrer. is. magnetic.. The. square. configuration.
offers.enhanced.mixing.efficiency.through.a.natural.baffling.effect.



















mixing.applications..Not. intended. for. sterile.applications:. suitable.














•. Wave. (GE. Healthcare),. 20. L. to. 1,000. L,. horizontal. oscillation. on. a.
rocker..The.rocking.motion.is.very.efficient.in.generating.waves,.and.
the.wave-induced.motion.in.the.bag.causes.large.volumes.of.fluid.to.
move. facilitating. the.dispersion.of. solids..The.optimum.operating.
parameters.depend.on.the.combination.of.the.container.geometry,.
bag. support,. filling. volume,. rocking. angle,. rocking. rate,. and. the.
characteristics.of.the.mixture.(solids,.foam,.etc.).














oscillating. movement. and. the. conical. orifices,. liquid. jets. develop.
at. the. tapered. end. of. the. holes.. Thus,. an. axial. fluid. flow. pattern.














while. the. kinetic. energy. moves. the. liquid. and. provides. a. mixing.










•. A. large. number. of. unit. operations. in. bioprocessing. involve. mix-
ing;.fortunately,.these.are.relatively.simple.operations.that.are.eas-
ily.validated.
•. The. largest. mixing. operations. involve. buffer. and. media. prepara-
tion.that.can.involve.thousands.of.liters..Since.these.components.are.
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nar. hood. in. those. environments. where. there. is. a. risk. of. cross-
contamination.to.reduce.any.additional.burden.on.filter.systems.
•. The.mixing. systems.available. today.are. the. same.as.used. in.dis-
posable.bioreactors:.in.some.instances.the.platform.can.be.used.for.
both.operations.
•. While. many. reputable. suppliers. have. developed. highly. sophis-
ticated. 3D. systems,. these. are. not. necessary. for. buffer. and. media.
preparations;.the.cost.of.3D.bags.with.built-in.stirring.systems.can.
be.prohibitive.
•. The. 2D. bags. offer. many. advantages. including. the. ease. of. storage.
because. they.are.horizontally. expanded;. the.wave.motion.created.
inside.these.bags.is.extremely.efficient.




























of.biological.drugs. requiring.many.control. features. that.were.not.needed.
or.required.in.other.industries..With.the.use.of.animal,.human,.and.plant.
cells.and.viruses.to.produce.therapeutic.proteins,.vaccines,.antibodies,.etc.,.
there. arose. a. need. to. modify. the. traditional. bioreactors. to. accommodate.
the.growth.needs.of.these.new.production.engines:.recombinant.engineer-
ing. put. these. new. engines. in. the. forefront. of. biological. drug. production..
One.major. change. in. the.design.of.bioreactors. that. is. recent. is. the.use.of.
disposable.bioreactors. to.avoid.the.challenges.of.cleaning.validation,. thus.
reducing.the.regulatory.barriers.in.drug.production..Hundreds.of.new.mol-
ecules. are. under. development. using. disposable. bioreactors,. and. in. many.
instances.disposable.bioreactors.are.used.to.manufacture.clinical.supplies..
















are. disposed. of. after. use;. they. may. come. with. several. attachments. that.
allow.the.filtration.of.media.and.monitoring.of.pH,.DO,.OD,.pCO2,. tem-
perature,. and. other. PAT-related. parameters.. Use. of. stirrers. and. paddles,.
and. shaking. and. rocking. the. bags. by. mechanical. or. hydraulic. means.
achieve.mixing.and.aeration.inside.the.bag..A.choice.of.aeration.systems.
may. include. surface. aeration. (e.g.,. in. Wave. Bioreactors). to. forced. sparg-
ing. through. proprietary. ceramic. tubes. (e.g.,. MayaBioReactors).. The. host.















low. fiber. system,. two-compartment. system,. multitry. cell. culture,.
static. bags. for. cell. expansion,. pneumatic. mixing. (peristaltic. recir-
culation),.and.rocking.bags..The.hollow.fiber. technology.required.
recirculation.of.media.to.grow.anchored.or.suspended.animal.cells.
using. the. Cellmax. HFBS. (FiberCell),. the. AcuSyst-HFBSs. (BioVest),.
and.the.Xcell.HFBS.(BioVest)..These.bioreactors.were.able.to.operate.























the. T-flask-based. CELLine. (INTEGRA. Biosciences,. Sartorius-
Stedim),.must.be.kept.in.a.CO2.incubator,.and.achieve.high.cell.
density.allowing.antibody.production.




























Pall,. EMD. Millipore,. New. Brunswick. Scientific,. and. Thompson. Scientific,.
adopted.3D.versions.of.disposable.bioreactors..The.recent.entrant.to.the.race.
is. Xcellerex,. which. has. done. well. with. its. large-scale. 3D. bioreactors.. The.
success.of.Xcellerex.comes.from.its.reputable.customer.support.as.they.build.
out. the.equipment.as.client. solutions,.while.others.position. themselves.as.
equipment.suppliers.
There.is.no.doubt.that.the.simplest.and.the.most.cost-effective.bioreactors.












Perhaps. the.equipment. suppliers’.profit.margins.were.not. large.enough.
or.perhaps.they.understood.the.psychology.of.the.industry.well.enough.to.
know.that.it.would.not.be.easy.for.Big.Pharma.to.come.down.from.tower-
ing.bioreactors. to. lay-flat.bags.with. rocking.motion.as. the.manufacturing.
equipment..This.caused.the.proliferation.of.3D.technologies..The.stirring.bag.
bioreactors.were.first. introduced.by.Thermo.Fisher’s.Single-Use.Bioreactor.
(SUB),. developed. as. a. result. of. cooperation. between. Baxter. and. Hyclone.
and.currently.the.market.leader;.this.and.the.XDR-Disposable.Stirred.Tank.
Bioreactor.from.Xcellerex.were.the.only.such.systems.available.initially..This.
was. followed.by.the.Nucleo.bioreactor. (ATMI.Life.Sciences),. the.BIOSTAT.
CultiBag.Stirred.(STR).(Sartorius.Stedim).(Figure 5.5),.the.Mobius.CellReady.








branes. wound. around. a. tumbling. stirrer,. all. features. making. it. a. simple.
reactor.to.operate.and.test.the.expression.of.new.cell.lines.(Figure 5.7).
Orbital.shaker.bioreactors.comprise. the. third-largest.category.after. the.































































cifically. designed. for. the. production. of. cell-culture-based. animal. cells..
The.FibraStage.is.kept.in.an.incubator.and.is.suitable.for.production.at.a.
laboratory.scale.(Figure 5.9).






























Oxygen. transfer. (which. is. described. by. the. volumetric. oxygen. transfer.
efficiency.rate.(KLa).values).and.its.influence.on.the.cultivation.result.have.






















The. wave-mixed. bag. bioreactors.have. secured. a. solid.position. in. mam-
malian. cell-derived. seed. train. manufacturing. and. process. developments.
aimed. at. producing. therapeutic. proteins.. These. bioreactors. are. run. in. a.






disposable. virus. production. bioreactors. (roller. flasks,. Cell. Factories). have.
been.successfully.replaced.by.wave-mixed.bag.bioreactors.
To.date,.wave-mixed.bag.bioreactors.have.proved.acceptable. for. the.culti-
vation.of.plant.cell.and. tissue.cultures. in. research.and.development. (R&D)..




alpha,. tumor-specific. human. antibody). were. successfully. produced. with.
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There. is. still. interest. in. developing. photo. bioreactors,. and. Applikon. has.
recently.made.a.disposable.offering.(Figure 5.10)..A.number.of.recent.studies.
have.demonstrated.that.normal.plants.could.be.grown.under.light-emitting.























tilation.and.requiring. less.cooling.for.growing.plants. in. the.culture.room..

















The. BIOSTAT. CultiBag. STR. of. Sartorius-Stedim. is. a. closed. system. and.
demonstrates. efficiencies. close. to. reusable. bioreactors.. As. an. option,.
the. bag. is. equipped. with. a. sparger. ring. or. a. microsparger. and. two. axial.
flow. three-blade-segment. impellers. or. a. combination. of. one. axial. flow.
three-blade-segment.impeller.and.one.radial.flow.six-blade-segment.impel-
ler.. Homogeneous. mixing. in. the. bag. is. achieved. by. the. centered. stirring.
system.
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ATMI. Life. Science’s. Nucleo. single-use. bioreactors. have. a. cube-shaped.
bag. instead. of. a. cylindrical. bag,. a. tumbling. (Pad-Drive). mixing. system.
instead. of. a. rotating. impeller,. and. a. dynamic. sparging. arrangement. in.
place. of. a. static. structure. and. is. available. in. 50. L. and. 1,000. L. volumes.
(ATMI.http://www.atmi-lifesciences.com).
Integrity™	PadReactor™






The.bioreactor.vessel,.which.offers. comparable. functionality. to. classical.
stirred-tank.bioreactors,. is.a. single-use.bag. integrating.an. internal.paddle.
mixing.and.sparger.system..This.innovative.bag.design.allows.a.noninvasive.







cleanroom. conditions. using. medical-grade. ultralow-density. polyethylene.
resin..It.is.then.laminated.to.create.a.gas.barrier.film.of.exceptional.cleanli-











allows. a. noninvasive. connection. to. the. mixer.. Mixing. is. achieved.
when. the. integrated. paddle/sparger. inside. the. bag. rotates. within.
the.bag.
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processes.•. Scalable. customizable. system.•. No. need. for. CIP/SIP.




Applikon. ez-Control. process. control. unit.. Similar. cell. densities. and. anti-
body.titers.can.be.achieved.in.the.Mobius.CellReady,.as.in.stirred.3.L.glass.















































In-seed. inoculum. productions,. process. developments. and. GMP. manu-
facturing.processes. for.mAb.products.and.vaccines,.and.wave-mixed.and.

















Disposable. bioreactors.have.not.played. an. important. role. to.date. in. the.
cultivation.of.cells.or.tissues.of.plant.origin.and.microorganisms..However,.
plant. cell. biomass,. secondary. metabolites. for.pharmaceutical. use,. cosmet-





















































York..This.was. indeed.a.game.changer. for. the. fermentation. industry.and.
resulted.in.the.birth.of.the.fermenter.industry.that.remained.true.to.the.first.
experiments.by.Pfizer.


















with. CFR. 21. requirements. eliminated. the. need. to. qualify. several.
batch.sizes.
•. Use.of.generic.bags.of.all. types.because.of. the.open.structure.of.
the.bioreactor.
•. The. least. expensive. fully. validated. cGMP-compliant. bioreactor. in.
the.world:.cost.savings.on.capital. investment.were.70%–90%.com-
pared.to.available.systems.and.cost.savings.for.ongoing.components.
50%+..This.opened.up. the.access.of.bioreactors. to. smaller. compa-
nies,.research.organizations,.and.developing.countries.










































































































SBB Nestlé 100.L.CV Cultivation.of.plant.cells:.
small-.and.medium-
volume-scale.manufacture
















Bioreactor	Brand Vendor Maximum	Size Main	Applications






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Disposable. components. came. into. use. first. in. the. field. of. connectors. and.
lines,.as.it.was.difficult.to.clean.them..Unlike.hard.piping,.the.flexible.tub-
ing.incorporated.into.disposable.transfer.lines.does.not.require.costly.and.
time-consuming. cleaning. and. validation.. This. allows. manufacturers. to.
quickly. change. process. steps. or. convert. over. to. a. new. product.. This. is. a.
key.advantage.for.multiple.product.facilities.in.which.process.requirements.
change.depending.on.the.drug.being.produced..Innovative.manufacturers.






This. process. requires. aseptic. transfer. at. each. point. along. the. seed. train..
Traditional. bioprocessing. facilities. accomplish. scale-up. using. a. dedicated.
series.of.stainless.steel.bioreactors.linked.together.with.valves.and.rigid.tub-
ing..For.these.systems,.to.prevent.contamination.between.production.runs,.



















Similarly,. disposable. tubing. assemblies. may. be. used. to. transfer. inocu-
lum. between. bioreactors. using. either. a. peristaltic. pump. or. headspace.












environment. to. a. lower-ISO. environment,. and. assurance. is. needed. that.











ject. to. the. safety. concerns. described. in. an. earlier. chapter. with. regard. to.
the.leachables.and.extractables..Several.attributes.of.flexible.tubing.require.
evaluation.such.as.their.heat.resistance,.operating.temperature.range,.chemi-
















elastomer. specifically. designed. to. meet. the. critical. demands. of. the.
medical,.pharmaceutical,.research,.biotech,.and.diagnostics.industries.
. . . C-Flex. biopharmaceutical. tubing. has. been. used. by. many. of. the.
world’s. leading. biotechnological. and. pharmaceutical. processing.
companies.for.over.20.years..Each.coil.of.C-Flex.tubing.is.extruded.


































cell.cultures..PharMed®.BPT.tubing. is. less.permeable. to.gases.and.vapors.




























Modified. polyolefin:. Tygon. LFL. (www.tygon.com);. chemically. resis-
tant,.flexible,.long-lasting
Modified.polyvinyl.chloride:.Tygon.LFL,.chemical.resistant,.long-lasting





Connections. between. bags. or. other. process. stages. are. done. by. fittings.
that.come.in.a.wide.range.of.configurations,.materials,.and.sterility..This.
includes. straight. couplers,. Y-couplers,. T-couplers,. cross. couplers,. elbow.
couplers,. and. barbed. plugs.. This. is. necessary. to. allow. ready. solutions.
to. go. through. the. often. complex. routines. of. liquids. in. a. bioprocessing.
facility.. The. size. of. these. connectors. ranges. from. 1/16. to. 1. inch. in. most.
instances;. often-incompatible. sizes. are. downgraded. or. upgraded. by.






















ical. power. transmission. such. as. from. Biovalves. (www.biouretech.com),.
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tube.may.produce.particles. from.erosion.of. the. tube.and.contaminate. the.
fluids.being.passed.through.
High-end. peristaltic. dispensing. pumps. have. benefited. from. improved.
pulsation-free.pump.head.design,.a.precise.drive.motor,.and.a.state-of-the-
art. calibration. algorithm.. They. are. exceptionally. accurate. at. microliter. fill.































mover. of. the. diaphragm. is. electromechanical,. working. through. a.






When. the. volume. of. a. chamber. of. either. type. of. pump. is. increased. (the.
diaphragm.moving.up),.the.pressure.decreases,.and.fluid.is.drawn.into.the.







































ilization.. These. are. called. SIP connectors.. Two. aseptic. systems. go. through.






























The. Opta®. SFT. Sterile. Connector. by. Sartorius-Stedim. (www.sartorius-
stedim.com).is.a.disposable.device,.composed.of.presterilized.female.and.














15. minutes. to. seconds. when. it. introduced. its. 1/2-in.. Kleenpak. Connector..
The.addition.of.the.two.new.Kleenpak.Connector.sizes.increases.flexibility.
to. implement.aseptic.connections. in.more.applications.to. improve.dispos-




ReadyMate. Disposable. Aseptic. Connector. (DAC). from. GE. Healthcare.
(www.gelifesciences.com). provides. connections. for. high-fluid. throughput.
and. offers. a. secure,. simple,. and. economical. connection. for. upstream. and.


























tube,. which. are. connected. to. the. aseptic. systems,. are. positioned. directly.
opposite. to.each.other.on.either.side.of. the.blade..A.welding.cycle.can.be.




(SEBRA,. www.Sebra.com),. TSCD. (Terumo,. www.terumotransfusion.com),.
and.SCD.11B.(Terumo)..(Terumo.supplies.its.equipment.mainly.to.the.blood.
















Moving. the. product. across. clean. rooms. may. involve,. at. times,. long. dis-
tances;.while.transfer.tubings.between.upstream.and.downstream.areas.and.





containment.barrier..The.second.connecting.part. is.an. integral.part.of. the.




















SART™. System:. The. SART. System. is. designed. to. allow. aseptic. liquid.
transfer.between.two.areas.with.different.containment.classifications.
Special. bags. have. therefore. been. developed,. for. example,. the. Biosafe.
Rapid.Aseptic.Fluid.Transfer.(RAFT).system.by.Sartorius-Stedim,.allow-






com),. Saint-Gobain. (www.saint-gobain.com),. Sartorius-Stedim. (www.
sartorius-stedim.com),. GE. Healthcare. (www.gelifesciences.com),. Terumo.
(www.terumotransfusion.com),. and. SEBRA. (www.sebra.com).. Most. of.











pling. systems.. A. popular. disposable. sample. valve. is. the. Clave. connector.





























much. of. the. disposable. technology. in. these. applications. has. come. from.






















which.is.consistent.with.our.current.drug.quality.system:.quality cannot be 




efficiency. in. pharmaceutical. development.. PAT. is. a. system. for. designing,.










time.. The. traditional. batch. analysis. such. as. high-pressure. liquid. chroma-












bance,. flow,. and. turbidity.. The. packages. that. contain. the. traditional. tech-
nologies. for.monitoring. these.parameters.are.not.usually.compatible.with.



















rial. properties,. sensor. manufacturing,. process. compatibility,. performance.






There. are. two. options. in. using. disposable. sensors:. one. where. the. sen-


















































These. sampling. systems. allow. aseptic. sampling. but. are. limited. by. the.
number.of.samples.taken.per.module.and.the.lack.of.automation..And.while.
these.methods.come.with.good.validation.data,. the. risk.of. contamination.
cannot.be.removed.since.the.bioreactor.is.indeed.breached.every.time.a.sam-



















An. example. of. this. is. the. fluorometers. from. BioView. system. (www.delta.
dk)..The.BioView.sensor.is.a.multichannel.fluorescence.detection.system.for.
application. in. the. biotechnology,. pharmaceutical. and. chemical. industries,.
food. production,. and. environmental. monitoring.. It. detects. specific. com-
pounds.and.the.state.of.microorganisms.as.well.as.their.chemical.environ-
ment. without. interfering. with. the. sample.. The. BioView. system. measures.




of. the.complexity.of. spectra.of.multiple.components,.high-level. resolution.
programming.is.required.
Finesse. Solutions,. LLC. (www.fiesse.com),. a. manufacturer. of. measure-
ment.and.control.solutions.for.life.sciences.process.applications,.announced.
a.live.demonstration.of.its.new.SmartBag.product.for.rocker.bioreactors.at.





















Many. metabolic. products. in. a. bioreactor. can. be. readily. detected. by. IR.
spectroscopy.but.water-absorbed.IR.beam.can.only.be.NIR.or.SIR.for.bio-
mass. analysis. when. used. in. the. transmission. mode.. However,. attenuated.
total.reflectance.spectroscopy.(ATRIR).is.based.on.the.reflection.of.light.at.
an.interface.of.two.phases.with.different.indices.of.refraction,.and.the.light.
beam. penetrates. into. the. medium. with. the. lower. refraction. index. in. the.






























Ocean. Optics. (www.oceanoptics.com). offers. the. world’s. first. miniature.
spectrometer.with.a.wide.array.of.sensors. for.oxygen,.pH,.and. in. the.gas.
phase.
The. pH. sensors. work. by. fluorescence. or. absorption,. and. for. fiber-optic.
pH.measurements,.both.fluorescence-.and.absorbance-based.pH.indicators.
can.be.applied..For.fluorescence,.the.most.common.dyes.are.8-hydroxy1,3,6-
pyrene. trisulfonic. acid. and. fluorescein. derivatives,. while. phenol. red. and.













































been. made. to. achieve. a. faster. response.. Fluorescence-based. sensors. are.
attractive.as. they. facilitate. the.development.of.portable.and. low-cost. sys-
tems.that.can.be.easily.deployed.outside.the.laboratory.environment..The.
sensor. developed. for. this. work. exploits. a. pH. fluorescent. dye. 1-hydroxy-
pyrene-3,6,8-trisulfonic. acid,. ion-paired. with. cetyltrimethylammonium.
bromide. (HPTS-IP),. which. has. been. entrapped. in. a. hybrid. sol–gel-based.



























dissolved. CO2. over. the. range. of. 1%. to. 25%,. with. an. accuracy. of. 5. %. of.
the.reading,.or.0.2%.absolute..Previously,.CO2.was.measured.either.in.the.
exit. gases. from. the. fermentation. process. or. by. taking. a. manual. sample..
The.new.optical-chemical.technology.uses.a.fiber-optic.cable.transfer.light.
through.a.stainless.steel.probe.into.a.disposable.sensor.capsule,.which.con-









































Fogale. (www.fogalebiotech.com). and. Aber. (www.aberinstruments.com),.
the.latter.now.offers.an.integrated.version.with.Dagsip.Biotools.Company.




























bioprocess. unit. operations. such. as. filtration,. chromatography,. and. many.
others.is.pressure..Using.a.traditional.stainless.steel.pressure.gauge.in.con-
junction.with.a.disposable.experimental.setup.is.possible,.but.has.the.draw-






















that. can. be. placed. in. an. autoclave. where. the. entire. device. is. exposed. to.
steam.. Many. single-use. process. components,. however,. are. not. compatible.


















single-use. sensors. from. PendoTECH. (www.pendotech.com). can. be. used.
with.tubing.of.various.sizes.(0.25.in..to.1.in..in.diameter).and.can.be.gamma.
radiated. with. tubing. and. bag. assemblies.. They. are. the. alternative. low-
cost.solution.for.use.with.tubing.and.bioprocess.containers.to.the.existing.
stainless.steel.pressure.sensors.on.the.market..Available.in.caustic-resistant.
polysulfone. so. they. can. be. in-line. during. caustic. sanitization. processes..
The.pressure.sensors.can.be.integrated.for.pressure.measurement.and.con-
trol. with. a. PressureMAT™. System. (monitor/transmitter). or. PendoTECH.
Process.Control.System.and.depending.on.the.number.of.sensors.and.pro-
cess. requirements.. The. data. collected. by. these. systems. can. be. output. to.




able. process. containers,. and. are. qualified. for. use. to. 75. psi.. Applications.
include.multistage.depth.filtration,. tangential.flow.filtration. (TFF)/cross-
flow.filtration,.and.bioreactor.pressure.monitoring.
NovaSensor’s. NPC-100. (www.ge-mcs.com). pressure. sensor. is. specifi-
cally.designed. for.use. in.disposable.medical. applications..The.device. is.
compensated.and.calibrated.per.the.Association.for.the.Advancement.of.
Medical. Instrumentation. (AAMI). guidelines. for. industry. acceptability..
The.sensor.integrates.a.high-performance,.pressure.sensor.die.with.tem-
perature. compensation. circuitry. and. gel. protection. in. a. small,. low-cost.
package.
The. SciPres. (www.scilog.com). combines. pressure-sensing. capabilities.
and.the.convenience.of.disposability.with.easy.setup..Each.sensor.is.pre-
programmed. and. barcoded. with. a. unique. ID. for. easy. traceability. and.







sensing. capabilities. in. a. compact,. disposable,. single-use. package. at. a. low.
price.point..Similar.to.the.SciPres,.each.sensor.is.preprogrammed.and.bar-
coded.with.a.unique.ID.for.easy.traceability.and.data.documentation.when.
combined. with. the. SciLog. SciDoc. software,. and. factory. calibration. data.






























been. an. evolutionary. process. with. a. few. revolutionary. peaks. here. and.


































separative.principles..The.protein.mixed.with.other. components. is. loaded.
onto.the.column.slowly,.and.once.it.is.bound.to.resin,.the.resin.is.eluted.with.
appropriate.pH.and.electrolyte.solutions.to.separate.the.target.protein.from.




































ReadyToProcess™. columns. are. prepacked,. prequalified,. and. presani-










the.development.of.efficient.processes. for.cell. culturing,.as.well.as. for.
purification.. Plug-and-play. units. make. several. time-consuming. steps.
redundant,. and. therefore. shorten. time. to. market.. Such. solutions. also.










applicable. process. consisting. of. MabSelect. SuRe,. Capto. Q,. and. Capto.
















and. the. development. work. was. concentrated. on. the. third,. polishing. step,.
where.the.multimodal.anion.exchanger.Capto.adhere.was.used.
The. feed. consisted. of. filtered. CHO. cell. culture. supernatant. contain-
ing.2.7.mg.mAb/mL..Sample.volumes.corresponding.to.25.mg.mAb/mL.
bed. volume. were. applied. to. the. XK. 16/40. and. RTP. MabSelect. SuRe. 2.5.
columns.. Five. cycles,. each. including. cleaning-in-place. (CIP). with. 0.5. M.
NaOH,.were.run.on.each.column,.and.the.eluates.were.collected.using.an.

















(CM015,. Cygnus. Technologies).. The. concentration. of. leached. MabSelect.
SuRe.ligand.was.determined.by.a.protein.A.ELISA.method.using.purified.
ligand.for.the.ELISA.standard.curve..The.analyses.were.not.optimized.for.
this. particular. feed. and. mAb.. Three-step. monoclonal. antibody. purifica-
tion. was. performed. in. parallel. at. two. different. scales.. The. overall. yield.
was.88%. for.both.processes,. achieving.contaminant. levels.acceptable. for.







Both. MabSelect. SuRe. columns. were. run. five. times. each. to. investigate.

























Capto. adhere. step. had. a. high. yield. and. efficiently. reduced. the. amount. of.
dimers.and.aggregates.in.this.study..With.this.particular.mAb,.it.was.neces-
sary.to.run.the.column.at.low.pH.(pH.5.0).and.high.salt.(0.4.M.NaCl).condi-
tions..At.these.conditions,. the.HCP.removal. is. limited..Typically,.when.the.
mAb.allows.running.at.higher.pH.and.lower.salt.conditions,.Capto.adhere.
also.removes.HCPs.
The. performance. of. ReadyToProcess. columns. is. comparable. with.
established. column. formats. as. has. been. demonstrated. in. a. three-step.
mAb. purification. process. run. in. parallel. at. two. different. scales:. small-
scale. XK. columns. and. large-scale,. prepacked. ReadyToProcess. columns..
The.ReadyToProcess.columns.behave.similarly. to. the.XK.columns. in.all.







A.disadvantage. in.using.resin.columns. is. the. large.footprint.required.
in.their.use;.compared.to.this,.membrane.chromatography.employs.thin,.
synthetic,.porous.membranes. that.are.generally.multilayered. in.a. small.
cartridge,.significantly.reducing.the.footprint.of.the.operation..Membranes.








ceutical. research. and. production.. But. chromatography. based. on. particu-










Sartobind. replaces. time-consuming. tedious. chromatographic. steps. for.
many.protein.and.virus.applications..The.rapid.purification.on.Membrane.













cross-linked. cellulose. network.. Diffusion. time. in. adsorbers. is. negligible.
because.of. the. large.pores.and. immediate.binding.of. the. target.substance.
to. the. ligands.. There. is. no. pore. diffusion. as. given. in. conventional. beads.



































IDA Metal.chelate  Iminodiacetic.acid >.3
Protein.A  Affinity  Protein.A 0.45
Epoxy-activated  Coupling  Epoxy.group 0.45
Aldehyde-activated  Coupling  Aldehyde.group 0.45
Source:.Sartorius-Stedim
A.special.advantage.in.the.use.of.membrane.adsorbers.is.the.removal.of.
high-molecular-weight. contaminants. such. as. DNA. and. viruses. in. mono-
clonal.antibody.manufacturing..Such.molecules.do.not.readily.diffuse.into.
the.pores.of.traditional.resins;.thus,.most.polishing.steps.relying.on.column.




Sartorius-Stedim. recently. introduced. single-use,. disposable. anion-
exchange.membrane.adsorption.cartridges. that.can.be.used. for.DNA.and.
host. cell. protein. removal. or. viral. clearance.. Likewise,. Pall. Corporation.
offers.a.similar.disposable.membrane.product.specifically.designed.for.DNA.
removal.. Other. companies. including. GE. Healthcare,. Millipore,. BioFlash.
Partners,. and. Tarpon. Biosystems. have. developed. prepacked. and. presani-
tized. disposable-format. chromatography. columns.. Most. of. these. columns.
were.designed.for.polishing.applications,.except.Tarpon’s,.which.can.be.also.




Virus. contamination. is. a. risk. to. all. biotechnology. products. derived. from.




Agency. (EMEA),. potential. contaminants. may. have. the. following. charac-
teristics:.enveloped.or.nonenveloped,.small.or.large,.deoxyribonucleic.acid.
(DNA). or. ribonucleic. acid. (RNA),. and. unstable. or. resistant. viruses.. Viral.
safety.of.licensed.biological.products.must.be.assured.by.three.complemen-
tary.approaches:
•. Thorough. testing. of. the. cell. line. and. all. raw. materials. for. viral.
contaminants




























Unfortunately,. the.risk.of. failing.viral.contamination. is.severe;.Table 8.1.
shows.the.action.plan.in.various.situations.
Implementing. ultraviolet. bactericidal. (UVC). treatment. as. one. of. the.






virus. inactivation,.and.virus.adsorption..UVivatec.shows.efficient. (>4. log).
inactivation. of. both. small. nonenveloped. viruses. (20. nm). and. large. envel-
oped.viruses.(>50.nm).form.a.biopharmaceutical.feed.stream.by.UV-C.irra-
diation.(254.nm).while.obtaining.product.integrity.
UVivatec,.a.newly.developed.virus. inactivation. technology,. targets.only.
small.and.nonenveloped.viruses.but.offers.a.robust.method.for.inactivating.










Case	A Case	B Case	C2 Case	D2 Case	E2
Status
Presence.of.Virus1 — — + + (+)3
Virus-like.
particles1
— — — — (+)3
Retrovirus-like.
particles1
— + — — (+)3
Virus.identified Not.
applicable



























































capital. equipment. expenditures,. time,. and. labor.. The. ChromaSorb. mem-
brane. consists. of. a. uniform. 0.65. µm. pore. structure,. ultrahigh-molecular-
weight.polyethylene.(UPE).membrane.coated.with.a.cationic.primary.amine.
ligand.for.high.binding.strength.for.negatively.charged.impurities.
Mobius. FlexReady. Solution. for. Virus. Filtration. from. Millipore. (www.
millipore.com). provides. the. best. combination. of. single-use. assemblies.
(Flexware. assemblies),. innovative. separation. devices,. and. process-ready.
hardware. specifically. designed. for. virus. filtration.. It. is. preassembled. and.
pretested,.and.integrates.easily.into.any.process..Designed.for.applications.









speed. control,. process. end-point. via. percent. flux. decay,. cumulative. vol-
ume/weight.or.processing.time,.innovative.low.dead.volume.t-connectors,.























Scale-down.work. is.being. realized.using. the.Virosart®.CPV.Minisart. (5.
cm2.capsule).to.enable.filtration.work.for.flow.and.capacity.studies.as.well.as.
for.GLP.virus.spiking.studies..Scale-up.studies.are.being.performed.using.
this. capsule’s. size. 9. with. filter. area. of. 2.000. cm2. to. reliably. scale. up. into.
larger-scale.manufacturing..Typical.batch.sizes.of.products.being.subject.to.
nanofiltration.with.this.Virosart®.CPV.capsule.size.9.are.5.to.50.L.
Pall. (www.pall.com). offers. Kleenpak. Nova. filters. with. either. in-line. or.
T-style. configurations.. The. T-style. configuration. is. ideal. for. manipulating.
multiple.filters.in.series.or.in.parallel.configuration..Kleenpak.Nova.Capsule.
filters. incorporate. either. a. 10. in.. (254. mm),. 20. in.. (508. mm),. or. 30. in.. (762.
mm). length. standard. Pall. cartridge. filter,. which. have. traditionally. been.
installed.in.stainless.steel.housings..In.applications.where.a.particular.filter.
is. already. specified,. the. user. can. switch. from. a. stainless. steel. housing. to.









































The.reduction. in.buffer.volume. is.necessary.because.of. the.high.cost.of.


















The. largest. disposable. holding. bags. currently. have. a. 3,000. L. capacity.
(Sartorius. Palletank),. while. mixing. with. disposables. is. limited. to. 5,000. L.












As. an. example. of. integrated. systems,. for. buffer. preparation. steps,. GE.
Healthcare. (www.gelifesciences.com). offers. its. WAVE™. Mixer.. The. WAVE.





















impact. on. process. efficiencies. and. final. product. quality.. Therefore,. nor-
mal.flow.filtration. is.one.of. the.first.steps. (after.dissolution). in.any.buffer.
preparation.process..Buffer.filtration.is.key.to.protection.of.chromatography.












leading. permeability. that. consistently. outperforms. competitive. offerings..
Both.filter.grades.are.constructed.using.a.polyethersulfone.0.2.micron.mem-
brane,.which.is.physically.robust.and.chemically.resilient,.so.they.perform.













with. ReadyToProcess. filters. and. sensors,. ReadyCircuit. assemblies. form.
self-contained. bioprocessing. modules. that. maintain. an. aseptic. path. and.
provide. convenience. by. removing. time-consuming. process. steps. associ-
ated.with.conventional.systems..Bags,.tube.sets,.filters,.and.related.equip-















tions.. It. is. factory. prepared. to. WFI. quality. for. endotoxins,. total. organic.













The. next. stage. for. handling. the. cell. mass. would. be. to. use. an. enzyme.


























pressure. forces. a. liquid. against. a. semipermeable. membrane.. Suspended.
solids.and.solutes.of.high.molecular.weight.are.retained,.while.water.and.
low-molecular-weight.solutes.pass.through.the.membrane..This.separation.
process. is. used. in. industry. and. research. for. purifying. and. concentrat-













































process. scale-up. and. production. for. early. clinical. phases.. System. meets.
Good.Laboratory.Practices.(GLP).and.current.Good.Manufacturing.Practices.




products/batches,. facilitates. easy. connection. to. and. operation. with. pre-
packed.ReadyToProcess™.columns.and.other.process.columns,.and.enables.
scalable.processes.using.UNICORN™.software.








Step ReadyToProcess Traditional %	Time	saving





































SciLog. (www.scilog.com). recently. developed. a. fully. automated,. single-
use.purification.platform.that.purportedly.improves.downstream.process-
ing. efficiencies. and. may. help. cut. costs.. Other. companies. are. developing.
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is.finally.washed.with.an.eluting.buffer. to.a.volume.that. is.generally. less.
than.5%.of.the.original.media.volume..This.process.eliminates.several.steps:.















The. bulk. product. is. generally. labeled. as. a. pharmacopoeia. product,. such.
as.“Erythropoietin.Concentrated.Solution.EP,”.and.would.thus.comply.with.


















for. simplifying. mobile. transfer. tanks.. These. tanks. with. disposable. liners.
are.designed.to.transfer.a.product.from.formulation.suites.to.storage.areas.
and.ultimately.to.filling.suites..To.allow.sterile.connection.to.and.from.these.
vessels,. designers. traditionally. add. three-way. valve. assemblies. to. fill. and.
drain.ports.to.facilitate.sterilization-in-place.(SIP).operations..The.design.of.




Single-use. tubing. assemblies. can. either. be. attached. prior. to. equipment.
sterilization.with.single-use.SIP.connectors.(used.as.either.steam.access.or.
condensate.drainage.sites),.or.steamed.separately,. just.prior. to.fluid. trans-
fer.. For. vessel. outlet,. combining. a. number. of. single-use. components. into.

































single.product..However,. this.approach. is.no. longer.economically. feasible.
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except. for. the. highest-volume. drugs. that. support. nearly. continuous. fill-










ing. operations. are. critical. enough. to. require. entire. single-use. systems. be.




eral. off-the-shelf. filling. systems. using. peristaltic. or. gravimetric. dosing..
Many. existing. systems,. however,. are. designed. for. low-speed,. small-batch.
filling.operations..Scale-up.of.these.systems.for.high-speed.filling.have.cre-






bagged. together. and. sterilized. using. gamma. irradiation.. The. assembly. is.
removed. from. the. bag. and. connected. to. the. filling. system,. which. can. be.





















The. current. single-use,. presterilized. dosing. systems. are. based. on. scal-
ing-up. technologies. designed. and. used. for. small-scale. filling. operations..
However,.a.better.approach. is. to.convert.existing.high-speed.dosing.tech-
nology.to.single-use..The.three.most.common.commercial.systems.are.piston.

























































racy. and. precision. over. its. operating. lifetime.. The. maximum. intended.
run.duration.for.commercial.systems.can. last. for.up.to.a.week.or.more.
and. involves.500,000. to.1,000,000.dosing.cycles.per.station..This. is.well.


























ing.operations. in.a.single-use. format..PreVAS.removes.several. risk. factors.




The. PDC. Aseptic. Filling. Systems. (www.lpsinc.net/pdc). specializes. in. the.
design.and.manufacture.of. innovative.filling.solutions.used.by.major.bio-
pharmaceutical. companies. (Figure  9.5).. Through. years. of. development,.
testing,.and.validation.by.major.biopharmaceutical.companies,.PDC’s.tech-
nology. allows. for. aseptic. filling. within. any. cleanroom. classification,. at. a.
fraction.of.fixed.stainless.steel.system.cost.and.manifold.filling.cost..Further,.
through.the.use.of.proprietary.disposable.fill.system.liners,.customers.have.









Other. solutions. for. filling. the. bulk. are. available. from. Sartorius,. Pall,.
and.Millipore.
The. Integrity™. LevMixer®. system. is. a. mobile,. flexible. mixing. system.
that. allows. efficient. and. reproducible. single-use. mixing. of. a. wide. range.













requires. no. dynamic. seals. or. shaft. penetration. inside. the. bag.. The. drive.
motor. is.enclosed.on.a.portable.cart. that.can.be.easily.disconnected. from.
the.bag.and.reconnected.to.another.mixing.bag,.allowing.mixing.in.multiple.
bags.of.various.sizes.with.a.single.drive.unit..As.with.all.ATMI.LifeSciences’.
single-use. mixing. systems,. the. LevMixer. utilizes. disposable. mixing. bags.
made. from.Integrity.TK8.bioprocess.film..The.product-contacting. layer.of.
TK8.film.is.blow-extruded.in-house.by.ATMI.under.cleanroom.conditions.
using. medical-grade. ultra-low-density. polyethylene. resin.. It. is. then. lami-
nated. to.create.a.gas.barrier.film.of.exceptional. cleanliness,. strength,.and.

























There. are. tremendous. advantages. to. the. use. of. single-use,. presterilized.
dosing.systems.for.commercial.filling.operations..Increased.processing.effi-





















filters. are. used. to. remove. a. high. contaminant. content. within. the. fluid..
Prefilters.have.a.large.band.of.retention.ratings.and.can.be.optimized.to.
all.necessary.applications..The.most.common.application.for.prefilters. is.
to.protect.membrane.filters. that.are. tighter.and.more.selective. than.pre-
filters.. Membrane. filters. are. used. to. polish. or. sterilize. fluids.. These. fil-
ters.need. to.be. integrity. testable. to.assess.whether.or.not. they.meet. the.

























































Filter. media. generally. comprises. layers. of. solid. materials. in. a. network. or.
mesh.with.voids,.pores,. and.channels. that.allow. the.passage.of. liquid.but.
retain.larger.particles,.larger.than.the.size.of.the.openings,.which.may.be.in.
nanometers.
Depth. filters. use. their. entire. depth. to. retain. particulate. on. the. basis. of.
sieving.compounded.by.adsorption.effects.unlike.retentive.filters.where.the.
filtered.material.is.concentrated.on.the.surface..The.depth.filter.media.domi-












Sheet. filters. are. also. made. like. paper. using. milled. cellulose. fibers. and.
may.contain.diatomaceous.earth.or.perlite.along.with.a.binder.to.strengthen.
the.filter.










as. no. binder. is. added. to. them.. These. are. always. the. preferred. filters. over.
polyamide.and.cellulose.filters..The.convention.method.of.their.manufacture.






















































































































The. main. advances. in. membrane. technology. (1960–1980). began. in. 1960.
with.the.invention.of.the.first.asymmetric.integrally.skinned.cellulose.ace-










































Two. basic. morphologies. of. hollow. fiber. membrane. are. isotropic	 and.






based. essentially. on. the. spatial. cross. section. of. the. permeating. species,.
that.is,.small.molecules.exhibit.a.higher.permeability.rate.through.the.fiber.




























Dense Dense/Selective Skin 




However,. it. also.has. some.disadvantages. that. contribute. to. its.application.
constraints..Among.the.disadvantages.are




•. Expensive:. Hollow. fiber. is. more. expensive. than. other. membranes.
that.are.available.in.the.market..It.is.because.its.fabrication.method.
and.expense.is.higher.than.other.membranes.








Hollow Fiber-Capillary Plate and Frame Spiral Wound 
•Very small diameter
membranes (< 1mm) 
• Consist large number of 
membranes in a module 
and self supporting. 
• Density is about 600 to 
1200 m2/m3. (for 
capillary membrane), up  
to 30000 m2/m3. (hollow  
fiber) 
• Size is smaller than 
other module for given 
performance capacity. 
• Process “inside-out”, 
permeate is collected 
outside of membrane 
• Process “outside-in”,  
permeate passes into  
membrane bore. 
• Structure is simple and 
the membrane  
replacement easy. 
• Similar to filter press 
• Density is about 100 to 
400 m2/m3. 
• Membranes is placed in a 
sandwich style with feed 
sides facing each other. 
• Feed flows from its sides 
and permeate comes out 
from the top and the 
bottom of the frame. 
• Membranes are held apart 
by a corrugated spacer. 
• Is formed from a plate and frame 
sheet wrapped around a center 
collection pipe 
• Density is about 300 to 1000 m2/m3. 
• Its diameter can up to 40cm. 
• Feed flows axial on cylindrical 
module and permeate flow into the 
central pipe. 
• Features: 
1. High pressure durability. 
2. Compactness. 
3. Low permeate pressure drop and 
membrane contamination. 
4. Minimum concentration 
polarization. 
• Ceramic membranes are usually  
monoliths of tubular capillaries. 
• Channel sizes are in millimeter range. 
• Becomes a module by attaching end 
fittings and a means of permeate 
collection. 
• Many monoliths are usually incorporated 
into one modular housing. 
• Not self supporting and normally are inserted in 
other materials’ tubes with diameter more than 
10mm. 
• Density is not more than 300 m2/m3. 
• Features: 
1. Can operate with simple pre-treatment of feed liquid. 
2. Membranes replacement is easy. 





between.a. few.membrane.separation.processes,. that. is,. the.microfiltration.
(MF),.ultrafiltration.(UF),.and.reverse.osmosis.(RO)..Occasionally,.one.will.
see.it.referred.to.by.other.names.such.as.“hyperfiltration.(HF).”.In.order.to.


























the. mid-1970s,. and. its. engineering. concepts. still. are. being. defined.. Many.
developments. that. initially. evolved. from. government-sponsored. funda-
mental.studies.are.now.successfully.gaining.the.interest.of.the.industries.as.
membrane.separation.has.emerged.as.a.feasible.technology.
Today,. membrane. polymers. used. in. pharmaceutical. processes. include.
polyvinylidene. fluoride. (PVDF),. expanded. polytetrafluorethylene. (ePTFE),.










































Hollow. fiber. devices. are. established,. for. example,. in. virus. clearance. by.
Asahi.Kasei.Medical.Planova®:
Planova. filters,. the. world’s. first. filters. designed. specifically. for. virus.
removal,.significantly.enhance.virus.safety. in.biotherapeutic.drug.
products,.such.as.biopharmaceuticals.and.plasma.derivatives..They.





Designed. specifically. for. use. in. cell. culture. clarification. applications,.
















reactor. perfusion,. and. culture. harvest. applications.. Very. similar. to. GE’s.
circulatory. system,. CellFlo. combines. the. advantages. of. tangential. flow.
microfiltration.(0.2.µm.and.0.5.µm.pores.sizes).with.larger.hollow.fiber.flow.
channels.(1.mm.ID).to.provide.gentler.efficacious.microseparations.without.
the. risk.of. cell. lysis..Other.cell. separation. technologies.have.a.higher. risk.
of.lysis.resulting.in.ruptured.cells.and.culture.harvests.contaminated.with.
intracellular.macromolecules..Perfectly.suited.for.continuous.cell.perfusion.
and. bacterial. fermentation,. CellFlo. membranes. isolate. secreted. proteins.










pore. sizes..Also. to.be. considered.are. the.MaxCell,. Spectrum.Laboratories.
CellFlo®,.and.KrosFlo®.module.families.
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from. Sartorius-Stedim.. They. also. keep. bringing. newer. filters,. housings,.
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arrangements,.and.recently. in.an. integrated.setup. in. their.disposable. fac-




















































plies,.and.more. recently.cell. therapy. that.holds.great.promise. for. the.dis-




validation,. calibration,. and. operational. qualification. of. the. equipment. are.
required..However,.this.does.create.a.challenge.especially.when.it.comes.to.
managing.characterization,.robustness,.and.scalability..The.fact. is. that.the.












lot-to-lot. variations. as. well,. and. this. is. where. some. problems. can. arise..
There.will.never.be. two.batches.of.a.biological.drug. that.are.always. the.
same;.variability.is.inherent.in.biological.systems.and.it.is.for.this.reason.
alone. that. regulatory. agencies. require. strict. environmental. and. compli-
ance.control.
To. demonstrate. how. the. FDA. views. the. single-use. or. disposable. tech-
nology,. a. review. of. the. Manual for Biologicals Compliance Program Guidance 
Manual,.Chapter.45—Biological.Drug.Products;.Inspection.of.Biological.Drug.
Products. (CBER). 7345.848,. implementation. date. of. October. 1,. 2010,. (www.
fda.gov/cber/cpg/7345848.htm),.has.one.entry.for.“single-use,”.and.none.for.
“disposable”.or.“plastic.”.The.entry.on.“single-use”.states.as.follows:





















are. other. features. of. a. facility. using. disposables,. including. how. this. can.
reduce.regulatory.barriers.that.should.be.considered.
One. of. the. easiest. and. perhaps. most. robust. means. of. assuring. lack. of.
cross-contamination.is.to.dedicate.a.facility.for.a.single.molecule;.this.way.
only. one. cell. line. enters. the. facility. and. only. one. molecule. goes. out;. all.
equipment.is.dedicated,.and.nothing.in.the.facility.is.shared.with.another.
operation. by. the. manufacturer.. The. cleaning. between. batches. remains. a.
task,. but. its. importance. is. significantly. reduced. as. no. new. contaminants.
are.expected..Dedicating.a.facility.to.one.molecule.is.not.possible.today.for.
most. companies. unless. they. happen. to. be. the. innovator. producing. very.
large.quantities.of.the.product..However,.the.smaller.footprint.required.in.
a.disposable.facility.can.make.it.possible.to.dedicate.facilities.to.individual.
molecules.. First,. the. elimination. of. sterilization-in-place. (SIP)/cleaning-




inate. the. large.engineering.infrastructure.needed.to.provide.water. in.the.
manufacturing. area.. It. is. projected. that. almost. 90%. of. the. water. used. in.






Another. design. element. that. reduces. the. footprint. of. a. manufacturing.

































In.many.cases,.microbial.control.or.sterility. is. required. to.ensure.product.
purity.and.safety..Radiation.sterilization. is.a.common.means.of.microbial.
control.and.sterilization.applied.to.single-use.systems..The.standard.meth-
ods. for. validating. radiation. sterilization. are. often. not. clearly. understood.
since.the.industry.has.mostly.operated.on.using.steam.sterilization;.however,.
a.keen.understanding.of.how.irradiated.components.are.validated.is.impor-



































































































































































of. Medical. Instrumentation. (AAMI),. the. International. Organization. for.
Standardization. (ISO),. and. ASTM. International. (formerly. the. American.





































Note:.. The.capital.cost. is. the.amortization.assuming.the.
facility.is.built.in.Europe.or.the.United.States.














In. microbiology,. it. is. impossible. to. prove. that. all. organisms. have. been.
destroyed.because.(1).they.could.be.present.but.undetectable.simply.because.
they.are.not.being. incubated. in. their.preferred.environment,.and. (2). they.



































the. greatest. assurance. of. sterility. for. critical. products. such. as. implantable.
devices.
SALs.describing.the.“Probability of a Nonsterile Unit”.(PNSU).are.expressed.
more.specifically.as.PNSU.in.some.literature.
Generally,.25.kGy.can.achieve.sterility.with.a.SAL.of.10–6..Even.with.ele-





































In.upstream.processing,.bacterial. (e.g.,.Escherichia coli). cell. cultures. tend.
to.be.operated.in.short.time.frames.and.are.fairly.resistant.to.overgrowth,.



















Even. at. the. stage. of. final. formulation. and. filling,. it. is. not. necessary. to.
claim. sterile. processing. as. a. nonsterile. finished. bulk. API. is. subsequently.





irradiated. health-care. products.. The. three. parts. of. ANSI/AAMI/ISO.
11137:2006.are
•. Part. 1:. Requirements. for. Development,. Validation,. and. Routine.
Control. of. a. Sterilization. Process. for. Medical. Devices. specifies.
requirements.for.development,.validation,.process.control,.and.rou-




•. Part. 2:. Establishing. the. Sterilization. Dose. describes. methods. that.
can.be.used.to.determine.the.minimum.dose.necessary.to.achieve.





aspects.of. establishing. the.maximum.dose. (product.qualification);.
establishing.the.sterilization.dose;.installation.qualification;.opera-
tional.qualification;.and.performance.qualification.





















buffer..The.buffer. then. is.removed.and.tested.for.bioburden. load.through.





















































































































































































































































































































































































































































































































































































































































Disposal.of. solid.waste. from.manufacturing.can.be.a. cumbersome. task.






























Appendix.C-I.(Recombinant DNA in Tissue Culture).states:	Recombinant.
DNA.molecules.containing.less.than.one-half.of.any.eukaryotic.viral.
genome.(all.viruses.from.a.single.family.being.considered.identical—






Biosafety. Committee. approval,. RAC. review,. and. NIH. Director.
approval.before.initiation,.(ii).experiments.described.in.Section.III-B.
which. require. NIH/OBA. and. Institutional. Biosafety. Committee.
approval.before.initiation,.(iii).experiments.involving.DNA.from.Risk.
Groups.3,.4,.or.restricted.organisms.(see.Appendix.B,.Classification.
of. Human. Etiologic. Agents. on. the. Basis. of. Hazard,. and. Sections.




Conditions for Cloning of Genes Coding for the Biosynthesis of Molecules 








Experiments. which. use. Escherichia coli. K-12. host–vector. systems,.
with. the. exception. of. those. experiments. listed. in. Appendix.
C-II-A,. are. exempt. from. the. NIH. Guidelines. provided. that:. (i).
the.Escherichia coli.host.does.not.contain.conjugation.proficient.
plasmids. or. generalized. transducing. phages;. or. (ii). lambda. or.
lambdoid.or.Ff.bacteriophages.or.nonconjugative.plasmids.(see.
Appendix.C-VIII..Footnotes and References of Appendix C).shall.be.
used.as.vectors..However,.experiments. involving. the. insertion.
into.Escherichia coli.K-12.of.DNA.from.prokaryotes.that.exchange.
genetic.information.(see.Appendix.C-VIII..Footnotes and References 
of Appendix C).with.Escherichia coli.may.be.performed.with.any.
Escherichia coli. K-12. vector. (e.g.,. conjugative. plasmid).. When. a.
nonconjugative.vector.is.used,.the.Escherichia coli.K-12.host.may.




experiments,. the. appropriate. physical. containment. conditions.





(i). experiments. described. in. Section. III-A. which. require.
Institutional. Biosafety. Committee. approval,. RAC. review,.
and. NIH. Director. approval. before. initiation,. (ii). experi-
ments.described. in.Section. III-B. which. require. NIH/OBA.and.
Institutional. Biosafety. Committee. approval. before. initiation,.





containment. conditions. specified. in. Section. III-D-2. with. prior.
Institutional. Biosafety. Committee. review. and. approval,. (iv).
large-scale.experiments.(e.g.,.more.than.10.liters.of.culture),.and.
(v). experiments. involving. the. cloning. of. toxin. molecule. genes.
coding.for.the.biosynthesis.of.molecules.toxic.for.vertebrates.(see.
Appendix.F,.Containment Conditions for Cloning of Genes Coding for 
the Biosynthesis of Molecules Toxic for Vertebrates).
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Appendix.C-III..Saccharomyces.Host–Vector.Systems






those. for. the.host.organism.unmodified.by. recombinant.DNA.







III-B. which. require. NIH/OBA. and. Institutional. Biosafety.
Committee. approval. before. initiation,. (iii). experiments. involv-
ing. DNA. from. Risk. Groups. 3,. 4,. or. restricted. organisms. (see.
Appendix.B,.Classification of Human Etiologic Agents on the Basis 
of Hazard,.and.Sections.V-G.and.V-L,.Footnotes and References of 
Sections I through IV). or. cells. known. to. be. infected. with. these.
agents.may.be.conducted.under.containment.conditions.specified.
in.Section. III-D-2.with.prior. Institutional.Biosafety.Committee.
review. and. approval,. (iv). large-scale. experiments. (e.g.,. more.
than.10.liters.of.culture),.and.(v).experiments.involving.the.delib-
erate.cloning.of.genes.coding.for.the.biosynthesis.of.molecules.
toxic.for.vertebrates.(see.Appendix.F,.Containment Conditions for 
Cloning of Genes Coding for the Biosynthesis of Molecules Toxic for 
Vertebrates).








experiments,. the. appropriate. physical. containment. conditions.









III-B. which. require. NIH/OBA. and. Institutional. Biosafety.
Committee. approval. before. initiation,. (iii). experiments. involv-
ing. DNA. from. Risk. Groups. 3,. 4,. or. restricted. organisms. (see.
Appendix.B,.Classification of Human Etiologic Agents on the Basis 
of Hazard,.and.Sections.V-G.and.V-L,.Footnotes and References of 
Sections I through IV). or. cells. known. to. be. infected. with. these.
agents.may.be.conducted.under.containment.conditions.specified.
in.Section. III-D-2.with.prior. Institutional.Biosafety.Committee.
review. and. approval,. (iv). large-scale. experiments. (e.g.,. more.
than.10.liters.of.culture),.and.(v).experiments.involving.the.delib-
erate.cloning.of.genes.coding.for.the.biosynthesis.of.molecules.
toxic.for.vertebrates.(see.Appendix.F,.Containment Conditions for 
Cloning of Genes Coding for the Biosynthesis of Molecules Toxic for 
Vertebrates).
In.addition.to.those.exemptions,.the.NIH.distinguishes.laboratory.use.from.


















Grade. A. =. Recyclable. plastic.. Pure. fractions. of. identified. plastics..
Examples:.Preparation.bags,.cell.culture.bags,.hold.bags,.cartridge.
bodies,.single.tubing,.tank.liners,.and.packaging.material..Currently,.
grade. A. wastes. constitute. a. small. percentage,. less. than. 10%. of. a.
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Grade. C. =. fractions. with. a. significant. amount. (>5%). of. nonplastic.
material. such. as. glass,. ceramics,. metals,. and. electronic. compo-
nents.. Examples:. cell. culture. bags. with. sealed-in. sensors,. pumps.
















widely-accepted. waste. treatment. option. with. many. benefits.. Combustion.








•. Directive. 94/67/EC. of. the. Council. of. the. European. Communities.








One.bioprocess.company.sends.all. its.waste. to.a.facility.that. incinerates.
and.uses.it.to.generate.electricity.for.a.major.U.S..city..Another.company.uses.





States.. In. the. United. States,. this. process. is. being. installed. increasingly. at.
universities,.hospitals,.and.housing.complexes.for.which.boilers.and.chillers.
can. serve. multiple. large. buildings.. In. the. European. Union,. the. European.










Pyrolysis. is.a.method. for.converting.oil. from.plastics. such.as.PE,.PP,.and.
polystyrene.(PS).that.can.be.used.as.fuel.for. internal.combustion.engines,.















disposal. costs,. this. may. change. rapidly;. in. most. instances,. this. would. be.
sourced.out.











landfilling.. This. option. is. appealing. because. it. may. be. accepted. as. safe.
in. some. cases. and. reduces. landfill. volume. compared. with. unshredded.
product..Additional.discussions.are.ongoing.regarding.use.of.other.hos-











nants. as. well.. Higher. temperature. treatment. up. to. 130°C,. or. gamma-ray.
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irradiation,. can. ensure. complete. destruction. of. all. temperature-resistant.
contaminants..One.potential.drawback.of.autoclaving.is.the.possible.pro-
duction. of. leachable. by-products. from. the. plastics. or. biopharmaceutical.
components,.which.can.also.result.from.predecontamination.with.chlorine.
dioxide,.leading.to.a.higher.risk.of.soil.and.water.contamination.through.
landfill. leakage.. The. use. of. chlorine. as. a. disinfectant. is. not. regarded. as.
environmentally. sound. because. it. can. lead. to. undesirable. atmospheric.
emissions..Wastes. that. are. strongly.acidic.or. caustic. through.contamina-
tion.with.pH.control.or.CIP.agents.must.be.neutralized.before.landfilling.






Some. companies. choose. landfilling.. Its. potential. as. an. option. varies.
based.on.municipal.and.regional.regulations.as.well.as.on.a.product’s.use.
before.disposal.






of. chlorine.dioxide.or.other.deactivator.and. then.dispose.of. the. item. in.a.
landfill..This.option.is.more.expensive.than.disposing.of.an.untreated.com-











may. also. be. released. from. landfilled. plastics. over. extended. periods. as.
aggressive.chemical.conditions.such.as.acidic,.caustic,.or.even.dilute.solvent.
microclimates.may.be.established..Furthermore,.high-temperature.pretreat-
ment. (presterilization).has. the.potential. to.convert.extractables. into. leach-
ables..The.assessment.of.the.risk.associated.with.extractables.and.leachables.









on. the. environment. that. matters.. Several. comprehensive. studies. have.





•. The. energy. footprint. of. stainless. steel. systems. far. outweighs. the.
energy.needed.to.incinerate.plastic.waste.










affecting. the. environment,. even. in. a. society. that. is. perhaps. the. greatest.
waste.producer.in.the.world,.the.United.States..However,.most.of.these.per-
ceptions. are. wrong. and. due. to. misinformation. from. the. defenders. of. the.
stainless.steel.industry,.which.should.begin.to.feel.the.shudder.from.these.
plastic.parts..Would. there.be.a. time.soon.when. there.will.be.biodegrade-
able.bioreactors?.Perhaps..Would. there.be.a. time.soon.when. there.will.be.
nonleaching.bioreactors.and.other.plastic.components?.Perhaps.sooner.than.








The. environmental. hazard. threat. from. disposable. components. is.












































to. be. pathogenic;. mutated,. recombined,. and. nonpathogenic. species. and.
strains. are. not. considered.. Noninfectious. life-cycle. stages. of. parasites. are.
excluded.
This.appendix.reflects.the.current.state.of.knowledge.and.should.be.con-




(see. Sections. V-C,. V-D,. V-E,. and. V-F,. Footnotes and References of Sections 
I through IV..Further.guidance.on.agents.not. listed. in.Appendix.B.may.be.
obtained. through. Centers. for. Disease. Control. and. Prevention,. Biosafety.




A. special. committee. of. the. American. Society. for. Microbiology. will.




RG1. agents. are. not. associated. with. disease. in. healthy. adult. humans..
Examples. of. RG1. agents. include. asporogenic. Bacillus subtilis. or. Bacillus 
licheniformis. (see. Appendix. C-IV-A,. Bacillus subtilis. or Bacillus lichenifor-
mis Host–Vector Systems, Exceptions);. adeno-associated. virus. (AAV). types.
1. through. 4;. and. recombinant. AAV. constructs,. in. which. the. transgene.
does.not.encode.either.a.potentially.tumorigenic.gene.product.or.a.toxin.
molecule.and.are.produced. in. the.absence.of.a.helper.virus..A.strain.of.
Escherichia coli. (see. Appendix. C-II-A,. Escherichia coli. K-12 Host–Vector 
Systems, Exceptions). is. an.RG1.agent. if. it. (1).does.not.possess.a. complete.
lipopolysaccharide. (i.e.,. lacks. the. O. antigen);. and. (2). does. not. carry. any.










Appendix B-II-A: Risk Group 2 (RG2)—









Bartonella henselae, B. quintana, B. vinsonii
Bordetella including B. pertussis
Borrelia recurrentis, B. burgdorferi
Burkholderia. (formerly. Pseudomonas. species). except. those. listed. in.
Appendix.B-III-A.(RG3))
Campylobacter coli, C. fetus, C. jejuni
Chlamydia psittaci, C. trachomatis, C. pneumoniae
Clostridium botulinum, Cl. chauvoei, Cl. haemolyticum, Cl. histolyticum, Cl. 
novyi, Cl. septicum, Cl. tetani




Escherichia coli—all. enteropathogenic,. enterotoxigenic,. enteroinvasive.
and.strains.bearing.K1.antigen,.including.E. coli.O157:H7
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ing.M..avium.complex,.M. asiaticum,.M. bovis.BCG.vaccine.strain,.M. 
chelonei, M. fortuitum, M. kansasii, M. leprae, M. malmoense, M. mari-




Neisseria gonorrhoeae, N. meningitidis
Nocardia asteroides, N. brasiliensis, N. otitidiscaviarum, N. transvalensis
Rhodococcus equi
Salmonella.including.S. arizonae, S. cholerasuis, S. enteritidis, S. gallinarum-
pullorum, S. meleagridis, S. paratyphi, A, B, C, S. typhi, S. typhimurium




Streptococcus.including.S. pneumoniae, S. pyogenes
Treponema pallidum, T. carateum
Vibrio cholerae, V. parahemolyticus, V. vulnificus
Yersinia enterocolitica
Appendix B-II-B: Risk Group 2 (RG2)—Fungal Agents
Blastomyces dermatitidis
Cladosporium bantianum, C. (Xylohypha) trichoides
Cryptococcus neoformans










Appendix B-II-C: Risk Group 2 (RG2)—Parasitic Agents
Ancylostoma.human.hookworms.including.A. duodenale, A. ceylanicum
Ascaris.including.Ascaris lumbricoides suum
Babesia.including.B. divergens, B. microti




Echinococcus.including.E. granulosis, E. multilocularis, E. vogeli
Entamoeba histolytica
Enterobius
Fasciola.including.F. gigantica, F. hepatica
Giardia.including.G. lamblia
Heterophyes
Hymenolepis.including.H. diminuta, H. nana
Isospora
Leishmania.including.L. braziliensis, L. donovani, L. ethiopia, L. major, L. 






Plasmodium. including. simian. species,. P. cynomologi, P. falciparum, P. 
malariae, P. ovale, P. vivax
Sarcocystis.including.S. sui hominis








Trypanosoma.including.T. brucei brucei, T. brucei gambiense, T. brucei rho-
desiense, T. cruzi
Wuchereria bancrofti.filaria.worms









Other. viruses. as. listed. in. the. reference. source. (see. Section. V-C,.




Other. viruses. as. listed. in. the. reference. source. (see. Section. V-C,.






Other. viruses. as. listed. in. the. reference. source. (see. Section. V-C,.
Footnotes and References of Sections I through IV)
Hepatitis.A,.B,.C,.D,.and.E.viruses




























Risk Group 3 (RG3)—Viruses and Prions). and. restricted. poxviruses.
including. Alastrim,. Smallpox,. and. Whitepox. (see. Section. V-L,.
Footnotes and References of Sections I through IV)












Appendix B-III-A: Risk Group 3 (RG3)—
Bacterial Agents Including Rickettsia
Bartonella
Brucella.including.B. abortus, B. canis, B. suis






Rickettsia akari, R. australis, R. canada, R. conorii, R. prowazekii, R. rick-
ettsii, R, siberica, R. tsutsugamushi, R. typhi (R. mooseri)
Yersinia.pestis
Appendix B-III-B: Risk Group 3 (RG3)—Fungal Agents
Coccidioides immitis.(sporulating.cultures;.contaminated.soil)
Histoplasma capsulatum, H. capsulatum.var...duboisii
Appendix B-III-C: Risk Group 3 (RG3)—Parasitic Agents
None




Venezuelan. equine. encephalomyelitis. virus. (except. the. vaccine.
strain.TC-83;.see.Appendix.B-II-D.(RG2))
Other. viruses. as. listed. in. the. reference. source. (see. Section. V-C,.











Other. viruses. as. listed. in. the. reference. source. (see. Section. V-C,.
Footnotes and References of Sections I through IV)
Orthomyxoviruses
Influenza.viruses.1918-1919.H1N1.(1918.H1N1),.human.H2N2.(1957-





Transmissible. spongioform. encephalopathies. (TME). agents.
(Creutzfeldt-Jacob. disease. and. kuru. agents)(see. Section. V-C,.









RG4. agents. are. likely. to. cause. serious. or. lethal. human. disease. for. which.
preventive.or.therapeutic.interventions.are.not.usually.available.
Appendix B-IV-A: Risk Group 4 (RG4)—Bacterial Agents
None.
Appendix B-IV-B: Risk Group 4 (RG4)—Fungal Agents
None.
Appendix B-IV-C Risk Group 4 (RG4)—Parasitic Agents
None.
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European. encephalitis,. Hanzalova,. Hypr,. Kumlinge,. Kyasanur.








































Appendix B-V-1: Murine Retroviral Vectors
Murine. retroviral. vectors. to. be. used. for. human. transfer. experiments. (less.
than.10.L).that.contain.less.than.50%.of.their.respective.parental.viral.genome.
and.that.have.been.demonstrated.to.be.free.of.detectable.replication.compe-




Appendix. K. specifies. physical. containment. guidelines. for. large-scale.
(greater. than. 10. liters. of. culture). research. or. production. involving. viable.
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organisms.containing.recombinant.DNA.molecules..It.shall.apply.to.large-
scale. research. or. production. activities. as. specified. in. Section. III-D-6,.
Experiments Involving More than 10 Liters of Culture.. It. is. important. to. note.










Scale. Practice;. (ii). the. institution. shall. appoint. a. Biological. Safety. Officer.
if. it. engages. in. large-scale. research.or.production.activities. involving.via-
ble. organisms. containing. recombinant. DNA. molecules.. The. duties. of. the.
Biological. Safety. Officer. shall. include. those. specified. in. Section. IV-B-3,.
Biological Safety Officer;. (iii). the. institution. shall. establish. and. maintain. a.
health.surveillance.program.for.personnel.engaged.in.large-scale.research.
or. production. activities. involving. viable. organisms. containing. recombi-
nant.DNA.molecules.which.require.Biosafety.Level. (BL).3.containment.at.
the.laboratory.scale..The.program.shall.include:.preassignment.and.periodic.






The. selection. of. the. physical. containment. level. required. for. recombinant.
DNA. research. or. production. involving. more. than. 10. liters. of. culture. is.
based.on.the.containment.guidelines.established.in.Section.III,.Experiments 
Covered by the NIH Guidelines..For.purposes.of. large-scale.research.or.pro-
duction,. four. physical. containment. levels. are. established.. The. four. levels.




scale. physical. containment. are. referred. to. as. Good. Large-Scale. Practice,.
BL1-Large. Scale,. BL2-Large. Scale,. and. BL3-Large. Scale.. Good. Large-Scale.





in. Appendix. C,. Exemptions under Section III-F-6,. which. have. built-in. envi-
ronmental. limitations. that. permit. optimum. growth. in. the. large-scale. set-
ting.but.limited.survival.without.adverse.consequences.in.the.environment..




production. of. viable. organisms. containing. recombinant. DNA. molecules.
that.require.BL2.containment.at.the.laboratory.scale..BL3-Large.Scale.is.rec-
ommended.for.large-scale.research.or.production.of.viable.organisms.con-
taining. recombinant. DNA. molecules. that. require. BL3. containment. at. the.
laboratory. scale.. No. provisions. are. made. for. large-scale. research. or. pro-











hand. washing. sink,. shower,. changing. room).and.protective. clothing. (e.g.,.
uniforms,.laboratory.coats).shall.be.provided.that.are.appropriate.for.the.risk.
of. exposure. to. viable. organisms. containing. recombinant. DNA. molecules..
Eating,.drinking,.smoking,.applying.cosmetics,.and.mouth.pipetting.shall.
be.prohibited.in.the.work.area.
Appendix. K-II-D.. Cultures. of. viable. organisms. containing. recombinant.
DNA.molecules.shall.be.handled.in.facilities.intended.to.safeguard.health.
during.work.with.microorganisms.that.do.not.require.containment.
Appendix. K-II-E.. Discharges. containing. viable. recombinant. organisms.
shall.be.handled.in.accordance.with.applicable.governmental.environmen-
tal.regulations.













Appendix. K-III-B.. Cultures. of. viable. organisms. containing. recombinant.
DNA.molecules.shall.be.handled.in.a.closed.system.(e.g.,.closed.vessel.used.
for.the.propagation.and.growth.of.cultures).or.other.primary.containment.
equipment. (e.g.,. biological. safety. cabinet. containing. a. centrifuge. used. to.
process.culture.fluids),.which.is.designed.to.reduce.the.potential.for.escape.
of. viable. organisms.. Volumes. less. than. 10. liters. may. be. handled. outside.
of. a. closed. system. or. other. primary. containment. equipment. provided. all.
physical. containment. requirements. specified. in. Appendix. G-II-A,. Physical 
Containment Levels—Biosafety Level 1,.are.met.
Appendix.K-III-C..Culture.fluids.(except.as.allowed.in.Appendix.K-III-D).
shall.not.be.removed. from.a.closed.system.or.other.primary.containment.
equipment. unless. the. viable. organisms. containing. recombinant. DNA.
molecules. have. been. inactivated. by. a. validated. inactivation. procedure.. A.













equivalent.procedures. (e.g.,. incineration). to.minimize. the.release.of.viable.
organisms.containing.recombinant.DNA.molecules.to.the.environment.
Appendix.K-III-F..A.closed.system.or.other.primary.containment.equip-








Appendix. K-III-G.. Emergency. plans. required. by. Sections. IV-B-2-b-(6),.





isms. containing. recombinant. DNA. molecules. are. immediately. reported.







Appendix. K-IV-B.. Cultures. of. viable. organisms. containing. recombinant.
DNA.molecules.shall.be.handled.in.a.closed.system.(e.g.,.closed.vessel.used.
for.the.propagation.and.growth.of.cultures).or.other.primary.containment.
equipment. (e.g.,. Class. III. biological. safety. cabinet. containing. a. centrifuge.
used. to. process. culture. fluids),. which. is. designed. to. prevent. the. escape.
of. viable. organisms.. Volumes. less. than. 10. liters. may. be. handled. outside.
of. a. closed. system. or. other. primary. containment. equipment. provided. all.
physical. containment. requirements. specified. in. Appendix. G-II-B,. Physical 
Containment Levels--Biosafety Level 2,.are.met.
Appendix.K-IV-C..Culture.fluids.(except.as.allowed.in.Appendix.K-IV-D).
shall.not.be.removed. from.a.closed.system.or.other.primary.containment.
equipment. unless. the. viable. organisms. containing. recombinant. DNA.
molecules. have. been. inactivated. by. a. validated. inactivation. procedure.. A.













cies. equivalent. to. high. efficiency. particulate. air/HEPA. filters. or. by. other.
equivalent. procedures. (e.g.,. incineration). to. prevent. the. release. of. viable.
organisms.containing.recombinant.DNA.molecules.to.the.environment.
Appendix.K-IV-F..A.closed.system.or.other.primary.containment.equip-







Appendix. K-IV-G.. Rotating. seals. and. other. mechanical. devices. directly.





























Appendix. K-IV-L.. Emergency. plans. required. by. Sections. IV-B-2-b-(6),.














DNA.molecules. shall.be.handled. in.a. closed. system. (e.g.,. closed.vessels.
used. for. the.propagation.and.growth.of. cultures).or.other.primary.con-
tainment.equipment. (e.g.,.Class. III.biological. safety.cabinet.containing.a.
centrifuge.used.to.process.culture.fluids),.which.is.designed.to.prevent.the.
escape. of. viable. organisms.. Volumes. less. than. 10. liters. may. be. handled.
outside.of.a.closed.system.provided.all.physical.containment.requirements.
specified.in.Appendix.G-II-C,.Physical Containment Levels—Biosafety Level 
3,.are.met.
Appendix. K-V-C.. Culture. fluids. (except. as. allowed. in. Appendix. K-V-D).
shall.not.be.removed. from.a.closed.system.or.other.primary.containment.
equipment. unless. the. viable. organisms. containing. recombinant. DNA.
molecules. have. been. inactivated. by. a. validated. inactivation. procedure.. A.










Appendix. K-V-E..Exhaust.gases. removed. from.a. closed. system. or.other.
primary.containment.equipment.shall.be.treated.by.filters.that.have.efficien-
cies. equivalent. to. high. efficiency. particulate. air/HEPA. filters. or. by. other.
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equivalent. procedures. (e.g.,. incineration). to. prevent. the. release. of. viable.
organisms.containing.recombinant.DNA.molecules.to.the.environment.
Appendix. K-V-F.. A. closed. system. or. other. primary. containment. equip-





















isms. containing. recombinant. DNA. molecules. shall. include. monitoring. or.
sensing.devices.that.monitor.the.integrity.of.containment.during.operations.



















Appendix. K-V-M.. Emergency. plans. required. by. Sections. IV-B-2-b-(6),.





















Appendix. K-V-N-7.. The. controlled. area. shall. be. designed. to. preclude.
release.of.culture.fluids.outside.the.controlled.area.in.the.event.of.an.acci-

























Appendix. K-V-O-3.. Entry. into. the. controlled. area. during. periods. when.
























Appendix. K-V-O-12.. Persons. working. in. the. controlled. area. shall. be.
trained.in.emergency.procedures.
Appendix.K-V-O-13..Equipment.and.materials. required. for. the.manage-
ment.of.accidents.involving.viable.organisms.containing.recombinant.DNA.
molecules.shall.be.available.in.the.controlled.area.














































5. Internal.accident.reporting. K-II-G K-III-A K-IV-A K-V-A




















































































NR NR K-IV-H K-V-I
16. Validated.integrity.testing.of.
closed.containment.system.

































Appendix. K-VII-D.. Containment.. Containment. is. the. confinement. of.
a. microbiological. agent. or. eukaryotic. cell. that. is. being. cultured,. stored,.
manipulated,.transported,.or.destroyed.in.order.to.prevent.or.limit.its.con-









K-VI-B,	Footnotes	of	Appendix	K] GLSP BL1-LS BL2-LS BL3-LS





NR NR NR K-V-N&O
Note:.. NR.=.not.required..The.criteria.in.this.grid.address.only.the.biological.hazards.associ-
ated.with.organisms.containing.recombinant.DNA..Other.hazards.accompanying.the.
large-scale. cultivation. of. such. organisms. (e.g.,. toxic. properties. of. products;. physical,.








Appendix. K-VII-G.. Good. Large-Scale. Practice. Organism.. For. an. organ-
ism. to. qualify. for. Good. Large-Scale. Practice. consideration,. it. must. meet.
the. following. criteria. [Reference:. Organization. for. Economic. Cooperation.




the. large-scale. setting. but. limited. survival. without. adverse. consequences.
in.the.environment;.(ii).the.recombinant.DNA-engineered.organism.should.



















Appendix. K-VII-K.. Pathogen.. A. pathogen. is. any. microbiological. agent.






























Long. ago,. Plato. raised. a. concern. in. his. Phaedrus that. is. familiar. in. our.









The. disposable. technology. of. today. was. only. a. tinkertoy. a. couple. of.
















































majority. of. which. is. represented. by. reactors. exceeding. 2,000. L.. With.
increasing. yields,. smaller. budgets. for. development,. and. increase. in. the.
diversity. of. development. projects,. the. future. of. bioprocessing. rests. on.








companies. to.make. it. to. the.market.first.and.allowing. the.expansion.of.
biotechnology. in. such. areas. as. cell. therapy,. stem. cell. applications,. and.
organ.growth.simulations.
Universal	Use




































contract. manufacturing. organizations. (CMOs),. contact. research. organiza-
tions.(CROs),.research.institutions,.and.small.companies.
Scale-Up
While. clinical. supplies. can.be.prepared.on.a. smaller.bioreactor,. the.man-












testing. several. batches.. In. the. future,. this. method. will. be. widely. used. to.
reduce. the. validation. requirements. for. different. size. batches,. and. entails.
only.conducting.mixing.validation.studies.
Cost
The. current. market. of. major. disposable. bioprocessing. equipment. is. con-
trolled.by.a.few.giants:.GE,.Pall,.Sartorius-Stedim,.EMD.Millipore,.Thermo.
Fisher.Scientific,.Xcellerex,.and.Saint-Gobain..A.large.number.of.small,.spe-
cialized. producers. of. equipment. are. filling. the. need. of. small-to-medium-
sized.bioreactors..It.is.not.surprising.that.many.of.the.leaders.are.emulating.
each.other. to. stay.competitive. in. terms.of. the. choices.available..However,.






































































from. filters. and. buffer. preparation. to. bioreactors,. equipment. suppliers.
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folds,. can. be. varied. and,. unless. these. are. standardized,. it. will. be. diffi-
cult. to. mix. and. match. suppliers. of. disposable. components.. Quantifying.
the. economic. benefits. of. single-use. systems. has. also. been. challenging.

















In. the. future,. biological. drugs. will. be. manufactured. very. differently..
From. the. possibility. of. cell-free. expression. systems,. such. as. Invitrogen’s.

















to. cut. down. the. entire. production. operation. in. the. upstream. area.. As. a.













in. ensuring. viral. clearance,. and. this. will. require. adopting. unorthodox.




ticularly. advantageous. for. vaccine. production. in. response. to. pandemic.
or.bioterrorist.threats.at.desirable.geographical.locations..Because.capital.
investment.is.relatively.lower.than.for.conventional.facilities.(and.opera-









be.prudent. for.Big.Pharma. to.outsource.manufacturing.of. their.biological.
APIs.. The. shift. that. took. place. 40. years. ago. when. the. manufacturing. of.





ary,.as.demand.and.supply.meet.and.as. the.awareness.of. the.cost. reduc-
tions.and.need.for.cost.reductions.collide..However,.the.real.changes.in.the.
universe. of. biological. manufacturing. will. come. from. deconstructing. the.






and,. when. it. reaches. a. certain. confluence,. allows. it. to. express. the. target.
protein,. all. of. which. can. be. done. swiftly. in. a. disposable. container. such.








the. force.applied.on. the. target.proteins. in. the. solution. reduce. the.yields..
The.question.arises.that.if.the.purpose.is.to.isolate.the.target.protein.from.
a.large.mass.of.culture.media,.why.are.components.such.as.cells.and.fluids.













be. used. to. disrupt. bacteria. in. the. culture. medium,. additional. chemi-







posal. of. GMOs. and. many. of. them. overbuilt. their. facilities. to. decontami-
nate.objects..In.those.cases.where.the.GMOs.fall.in.the.exempt.category.of.
biosafety,.such.as.recombinant.CHO.cells,. these.may.be.discharged.in.the.








Autoclaves. will. not. be. needed:. the. GMO. contact. surfaces. and. effluents.











the. bags,. removing. the. need. for. a. holding. tank. and. allowing. direct. dis-
charge.in.sewer.systems.
SIP/CIP








It. is.customary.for. the. industry.to.have.a.stainless.steel. loop.of.distilled.
water.run.at.80°C..The.preparation.of.distilled.water.involves.water.puri-
fication,. deionization,. boiling. water,. condensing. water,. storing. distilled.





















































is. need. to. handle. Teflon:. the. current. manufacturing. technology. would.















Target. protein-specific. resins. will. be. developed. that. will. allow. fewer.
steps.in.downstream.purification..The.example.of.Protein.A.as.a.capture.
resin. for.monoclonal.antibodies.will.be.extended. to.other. types.of. res-












chromatography.systems.disposable.will.not.be.needed. if. the.equipment. is.




Completely. closed. systems. wherein. buffers,. media,. protein. capture,. and.
initial.purification.remain.enclosed.will.allow.the.use.of.environment.con-
ditions.that.are.less.expensive.to.maintain,.for.example,.the.use.of.a.500K.

























The. greatest. hurdle. in. providing. sufficient. oxygen. for. the. ever-higher.
expressing.cell.lines.has.been.removed.by.novel.sparging.systems.to.deliver.
oxygen.mass.transfer.capacity.of.10.mmol/L/h.(KLa.=.50/h).when.50.×.106.
cells/mL.are.cultivated..For.microbial.systems,. like.an.E. coli. fermentation.
at.50.g/L.dry.cell.weight,.the.required.mass.transfer.capacity.has.to.be.200.
mmol/L/h.(KLa.>.800/h).or.even.higher..More.advances.will.be.made.in.the.
use. of. disposable. bags. that. will. be. available. with. integrated. sensors. and.
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